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Abstract
THE ROLE OF ATP AND CLEAVAGE FACTOR PHOSPHORYLATION
IN PRE-MRNA 3’ CLEAVAGE REACTION

by
Asya Khleborodova
Advisor: Kevin Ryan
The 3’ end cleavage/polyadenylation (3’ processing) is important in generating a functional
messenger RNA (mRNA) transcript. It is long-known that ATP can significantly stimulate the in vitro
cleavage of adenovirus type 2 L3 (Ad2L3) RNA substrate. Here, we used ATP analogs in structureactivity assays to show that the structural features of ATP and its analogs determine in vitro 3’ cleavage
efficiency. More specifically, we demonstrate that the structure of the nitrogenous base, the nucleotide
sugar and the triphosphate group contribute to the efficiency of the nucleotide-stimulated in vitro 3’
cleavage reaction.
It was found that AppNp, an analog of ATP whose gamma phosphate cannot be transferred
enzymatically or chemically to water (ATPase activity) and cannot serve as a phosphate donor for a
protein kinase, is capable of stimulating cleavage. This finding led us to the conclusion that ATP likely
functions as an allosteric activator of some protein involved in 3’ cleavage activity. The structure-activity
relationship studies we carried out also showed that AppCp, another ATP analog whose gamma
phosphate cannot be transferred, was an in vitro 3’ cleavage reaction inhibitor with an IC50 of
approximately 300 M. Taken together, our experiments provide indirect evidence that ATP (and certain
analogs) stimulate 3’ cleavage by simply binding to one of the 3’ cleavage factors, and that their
structures determine the efficiency of the 3’ cleavage reaction. Using the in vitro cleavage reaction, sitedirected mutagenesis and co-immunoprecipitation (co-IP) we furthermore show that cleavage factors
CFIm25, PAP and Clp1 are not likely to be the agencies of ATP action.
From previous research in our lab we know that in vitro dephosphorylation of 3’ processing
proteins, specifically cleavage factors I and II (denoted as CFm when unseparated), results in the
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suppression of the 3’ cleavage. We carried out experiments aiming to identify the phosphorylated
cleavage factor(s) that can restore 3’ cleavage activity to dephosphorylated HeLa cell nuclear extract
(NxT). It was determined that immunopurified Flag epitope-tagged-CFIm25, -Clp1, -CFIm68, -CFIm59,
and tag-independent immunopurified Pcf11, when used in place of CFm, were not capable of restoring 3’
cleavage activity to dephosphorylated NxT, and therefore likely do not contain an activating amount of the
unidentified phosphorylated cleavage factor.
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CHAPTER ONE: Survey of precursor mRNA (pre-mRNA) 3’-End Processing
1.1

Protein Factors Involved in pre-mRNA 3’ End Formation

1.1.1

Introduction
The 3’ end cleavage/polyadenylation of pre-mRNA is a co-transcriptional processing event that

along with 5’ capping, splicing, and RNA editing leads to formation of a mature or translation-ready mRNA
(1). Occurring in the nucleus, and formally between transcription and translation, RNA processing events
are in position to influence gene expression patterns (2). In this study, the focus is on understanding the
3’ processing mechanism in the context of protein phosphorylation, as well as the 3’ cleavage reaction.
The 3’ processing mechanism involves endonucleolytic cleavage of the pre-mRNA at its 3’ end
followed by polyadenylation, i.e. synthesis of a ~250 nt poly(A) tail. For these two steps to take place, a
large complex of proteins has to recognize three major cis elements on the pre-mRNA and assemble into
a functional 3’ processing protein complex (3). The 3’ processing defines 3’ untranslated region (UTR) of
the pre-mRNA, a region between the stop codon and the poly(A) tail. In eukaryotes, the 3’ processing can
producing multiple mRNA isoforms via a mechanism known as alternative polyadenylation (APA) of the 3’
UTR (4). If APA takes place in the upstream regions of the UTR, it can lead to exclusion of the regulatory
cis-elements, like AU-rich elements (AREs) and microRNA (miRNA) binding sites (5). These cis-elements
of 3’ UTR regulate gene expression by determining stability and half-life of the mRNA. APA controls the
gene expression patterns in immune and neural cells, as well as during stem cell differentiation,
oncogenesis, and development (6-10). Defective 3’ processing has been linked to a number of human
diseases, making it important to understand the functions and regulation of the 3’ processing mechanism
(9).
Such 3’ processing cis elements as AAUAAA hexamer, downstream U- and GU-rich sequences,
and upstream UGUA motifs have been identified through genetic and bioinformatics studies (11). Proteins
involved in the 3’ processing (i.e., the cleavage factors) were characterized using biochemical and
structural studies (12). The functions of many of these proteins have been determined as well as their
protein-protein interaction networks and assembly into 3’ processing complex (11). A number of
regulatory mechanisms for 3’ processing have been discovered, mainly regulation of this process is
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determined by the levels of the basal 3’ processing factors, or by regulatory factors and local RNA context
(1).
The next step in the 3’ processing research is to understand how the proteins of this mechanism
function to recognize the cis elements of the pre-mRNA, assemble into a functional complex, catalyze
accurate 3’ cleavage, and disassemble from the 3’ complex.
Our focus in this project is to understand the functioning of the 3’ end processing in two separate
contexts. From previous research in our lab we know that in vitro dephosphorylation of 3’ processing
proteins results in suppression of the 3’ cleavage (13). Our goal is to further investigate this insight and
find the protein(s) that require phosphorylation for cleavage. In addition, we know that ATP is required for
in vitro cleavage of Ad2L3 RNA substrate, a pre-mRNA substrate that is thought to be representative of
most RNA substrates (14). As a result, we wanted to see if this ATP requirement is part of
phosphorylation-dependent 3’ cleavage. In other words, is ATP being used as a substrate in a
kinase/phosphatase mechanism for phosphorylation of protein(s) in the 3’ processing complex? Or
alternatively, is it stimulating 3’ cleavage by acting as a protein-binding cofactor, and if so, what are its
target proteins?
1.1.2

General Description of Protein Factors Involved in pre-mRNA 3’ End Formation
Most eukaryotic pre-mRNAs undergo processing reactions before they are exported to the

cytoplasm for translation (15). These reactions, 5’-cap addition, editing, splicing, and 3’ cleavage and
polyadenylation, usually occur co-transcriptionally and are interconnected with each other and translation
(16).
The 3’ processing occurs in all eukaryotic pre-mRNA, except for the histone-coding mRNAs,
which undergo an AAUAAA-independent 3’ cleavage and are not polyadenylated (17). Poly(A) end
formation is a two-step process that involves cleavage that is carried out by a complex of proteins and
subsequently the addition of the poly (A) tail. Several 3’ cleavage and polyadenylation proteins assemble
into a protein complex on C-terminal domain of RNA polymerase II (RNAP II) during the 3’ cleavage
reaction (Fig 1A) (18). Using fast protein liquid chromatography (FPLC) and HeLa (NxT), this protein
complex can be purified and separated, on the anion exchange column also known as a DEAEsepharose column, into three main cleavage activities, the cleavage and polyadenylation specificity factor
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(CPSF), the cleavage stimulation factor (CstF) along with PAP, and the mammalian cleavage factor
(CFm) (13). Since symplekin forms a stable subcomplex with CPSF and CstF, it is thought to function as
a scaffolding protein (12). Poly(A) polymerase (PAP) synthesizes the 200-250 nucleotide poly(A) tail (19).
In mammals, PAP is required for both cleavage and polyadenylation of most substrates in vitro, except for
simian virus 40 late pre-mRNA (SV40L), in which case it is required only for polyadenylation but not the 3’
cleavage, and its interactions with other 3’ processing proteins are important for defining the proper length
of the poly(A) tail (12, 20). Nuclear poly(A) binding protein 1 (PABPN1) stimulates poly(A) tail elongation
and controls the length of the poly(A) tail through interactions with PAP and CPSF (2).

Figure 1. The 3’ processing protein complex assembly on the pre-mRNA. A. 3’ processing protein
factors are shown to recognize and assemble on cis elements of 3’ cleavage/polyadenylation site. The
site of cleavage is indicated with arrow. B. Each 3’ processing factor, except for CFIIm, is broken down
into its most characterized proteins and shown to bind to its cis element. Protein-protein interactions
within each factor but not inter-factor interactions are shown here.
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1.1.3

Pre-mRNA Cis Elements
For 3’ processing to take place at the correct location on the pre-mRNA transcript, the 3’

processing complex has to bind to and assemble on the combination of specific upstream and
downstream cis elements of that transcript (3). The pre-mRNA cis elements guide the assembly 3’
processing complex and the location of 3’ cleavage and polyadenylation. In metazoans, the site of
endonucleolytic cleavage does not have a specific sequence, however, it does usually occur directly after
a CA dinucleotide (21). The main cis element is AAUAAA hexamer, also known as polyadenylation signal
(PAS). It is located 10 to 35 nt upstream of the cleavage/polyadenylation site (pA site) (1). This element is
the most highly conserved of all 3’ processing cis elements, although it does show some
microheterogeneity (22). Single mutations of almost any one nucleotide in this cis element, results in loss
of cleavage activity and polyadenylation in vitro (23, 24). In humans, genetic mutations in AAUAAA
hexamer lead to such diseases as thalassemia and thrombophilia (25). Other important 3’ processing cis
sequences are a U/GU-rich downstream elements (DSEs) ~30 nt downstream of the pA site. These are
bound by CstF. There are also the multiple UGUA motifs that occur 40 to 100 nt upstream of the pA site.
These motifs are bound by CFm (26). Overall, there are three main pre-mRNA cis elements that define
the location of and help the 3’ processing proteins recognize the pA site. Twenty to thirty percent of all pA
sites lack AAUAAA motif, these sites are known as non-canonical pA sites (1). The mechanism by which
these sites are recognized is not known, however, such sites are associated with APA sites and some
share sequence similarity to yeast and plant pAs.
1.1.4

3’ Processing Factors
The main 3’ processing factors have been identified; they are CPSF, CstF, CFm, PAP, RNAP II

C-terminal domain (CTD), and PABPs. Their specific roles in 3’ processing have to a varying extents
been established. All factors except PABPs are required for 3’ cleavage, while CPSF and PAP alone can
bring about poly(A) tail synthesis (1). PABPs are not required for 3’ cleavage or polyadenylation, instead
these proteins stimulate efficient PAP activity and function to determine the length of the poly(A) tail (27).
Despite the differences between the mammalian and yeast cis elements, yeast homologs exists for most
mammalian 3’ processing proteins, indicating that the basic 3’ processing structure and mechanism are
conserved from yeast to mammals (11).

4

HeLa NxT was used to do in vitro 3’ cleavage reactions for that part of the project when we were
looking for the protein(s) that required phosphorylation in order for 3’ cleavage to occur. However, for the
reactions with ATP or its analogs, we used DEAE-sepharose fractionated factors CstF/PAP, CFm and
CstF were used to do 3’ cleavage reactions. Hence, the role of ATP in the 3’ cleavage reaction was
explored not in relation to HeLa NxT but in the context of partially purified 3’ processing factor fractions.
1.1.5

CPSF
The CPSF fraction consists of 30 kD, 73 kD, 100 kD, 160 kD, Fip1 and WDR33 proteins (3).

Three main functions are assigned to CPSF. First, CPSF functions to recognize the highly conserved
PAS hexamer, AAUAAA (28). Second, CPSF assembles the 3’ processing complex around the PAS
signal through its protein-protein interactions with other 3’ processing factors (29). Third, CPSF73 carries
out the endonucleolytic cleavage of the pre-mRNA (30).
1.1.6

CPSF-RNA Interactions
Until recently CPSF160 was thought to bind to and recognize the AAUAAA hexamer (28).

However, a recent new study into CPSF binding to AAUAAA element revealed that WDR33 (146 kD) and
CPSF30 directly bind to and recognizes the main cis element (AAUAAA) on the pre-mRNA during 3’
processing (31). It was determined that zinc fingers (ZF) 2 and 3 of CPSF30 were responsible for binding
to AAUAAA. In line with this is the observation that the influenza protein NS1A is known to bind to
CPSF30 and abolish host 3’ processing, perhaps preventing CPSF30-AAUAAA interaction (32).
Therefore, it may be that the CPSF30-AAUAAA interaction is the hub for 3’ processing recognition and
assembly. WDR33 has been implicated in direct binding mainly to the AAUAAA element and within 12 nt
just downstream of this element (31). WDR33 contains three major and very different domains, one of
which is WD40. WD40 domain is usually responsible for protein-protein interactions (33). However, for
WDR33 protein this domain had been known to bind to RNA (34). Yeast homolog of WDR33, Pfs2 is
smaller and contains only the WD40 domain. In yeast, Pfs2 is required for cell survival and
polyadenylation (35). As for CPSF160 interaction with RNA, a much earlier study showed that in HIV premRNA, CPSF160 binds to an enhancer element 75 nt upstream of AAUAAA (36). Another CPSF protein
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Fip1, through its C-terminal arginine-rich domain, binds to auxiliary U-rich regions upstream of AAUAAA
element (37).
1.1.7

Protein-Protein Interactions of CPSF
CPSF binds to the transcription machinery early in the RNA transcription phase by binding to the

transcription factor, TFIID and associates with RNAP II throughout the transcription process (38).
Consequently, it is possible that CPSF is the 3’ processing factor that initiates the 3’processing protein
complex assembly. Although, another study found that pre-incubation of CFIm with pre-mRNA reduced
the lag phase and enhances its activity (39). CPSF73 is the endonuclease that carries out the 3’ cleavage
reaction. CPSF73 together with CPSF100 and symplekin are thought to form the core complex of 3’
cleavage of both poly(A) and histone mRNAs (40, 41). With the recent discovery of WDR33 and CPSF30
binding to AAUAAA element, it is now thought that these proteins together with Fip1 and CPSF160, which
bind to U-rich element just upstream of AAUAAA, recognize the poly(A) site while CPSF100, CPSF73,
and symplekin complex carries out the 3’ cleavage reaction (41). The histone 3’ cleavage occurs under
similar circumstances where SLBP and U7 snRNP recognize SL and HDE cis elements, while CFST100,
CPSF73, and symplekin complex carries out the 3’ cleavage reaction (41).
CPSF can be isolated together with CstF, this association between the two factors is maintained
through CPSF160, Fip1, and symplekin (29, 37, 42). CPSF160 structure consists of WD40 repeats that
make up the three major β-propeller domains (43). CPSF160 can cross-link to pre-mRNA (28). CPSF160
has been shown to directly interact with CstF77 and has weak binding with PAP (29).
Fip1 appears to cross-link to pre-mRNA region 13 nt upstream of the AAUAAA element (31).
Human Fip1 is known to bind to PAP, CPSF160, CPSF30, and CstF77 (37). Fip1- PAP binding has been
identified across different species, despite the low amino acid residue conservation in both Fip1 and PAP
at their region of contact (44). Fip1 appears to largely function as a scaffolding protein that binds to premRNA and maintains protein-protein interactions.
CPSF73 protein has been identified as the 3’ cleavage endonuclease. From its sequence,
CPSF73 is known to belong to metallo-β-lactamase (MβL) superfamily of hydrolase proteins that are
dependent on metal ions (30). The crystal structure of CPSF73 shows that the active site is buried at the
interface of the β-CASP and MβL domains. Such positioning of the active site precludes pre-mRNA
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binding to CPSF73 (30). The positioning of the active site within CPSF73 may indicate that this protein
requires the help of another protein for binding to its pre-mRNA substrate.
CPSF100 protein is also part of a MβL superfamily of endonucleases (30). Although CPSF100
belong to a family of endonuclease, this protein cannot carry out catalysis due to its lack of the amino acid
residues that coordinate the two catalytically active zinc ions of this superfamily. The exact function of
CPSF100 is not yet known, however, it is suspected that CPSF100 protein and CPSF73 endonuclease
interact through their C-terminal domains. Since CPSF73 purified from HEK293 cells had no 3’ cleavage
active suggests (45) that CPSF73 does not self-dimerize but instead may dimerize with CPSF100 to
become a catalytically active protein (12). Hence, CPSF100 may be required for catalysis. Pulldown
assays revealed that Ydh1, yeast homolog of CPSF100, associates with RNAP II CTD and Pcf11,
indicating that Ydh1 may function in cross-talk between transcription and 3’ processing (46).
CPSF30 is required for both 3’ cleavage and poly(A) tail addition. This protein consists of five ZF
domains and one zinc knuckle domain (47). From earlier studies, CPSF30 is known to UV cross-link to Urich regions located close to AAUAAA element (26, 47). From more recent studies CPSF30 has been
shown to directly bind to AAUAAA element though ZFs 2 and 3 (31). Crystal structure studies show that
ZFs 2 and 3 of CPSF30 directly interact with NS1A protein of the influenza virus (32).
WDR33 has the N-terminal WD40 domain that has been shown to bind to pre-mRNA (34). In
yeast, WDR33 homolog, Pfs2 is known to directly interact with yeast homologs of mammalian CPSF73,
CstF77 and Fip1 proteins (35). This finding indicates that WDR33 may be bridging CPSF-CstF
interactions and therefore besides binding to the AAUAAA element, WDR33 may also play a role in
assembly of the 3’ processing complex. WDR33 could be helping CPSF and CstF bind to their respective
pre-mRNA cis elements, AAUAAA and DSE.
1.1.8

CstF
CstF is another major 3’ processing factor that is essential for both 3’ cleavage and

polyadenylation (12). The main role of CstF is to facilitate interactions between CPSF and CstF proteins
and assist in their cooperative binding to their corresponding cis elements (48). CstF recognizes the less
conserved G/U- and U-rich DSEs that occurs 30 nt downstream of the cleavage site (49). The CstF factor

7

contains three proteins 50 kD, 64 kD, and 77 kD (50). Each of the proteins occurs as a dimer (51). The
CstF77 protein assembles and maintains the CstF factor (42).
1.1.9

CstF-RNA Interactions
CstF64 is responsible for binding DSE through its N-terminal RNA recognition motif (RRM) (49).

On its own CstF64 has high binding affinity for GU- and U-rich elements. The two elements are located
within 15 nt of each other (26), which could mean that these cis elements are simultaneously bound by
two copies of CstF64. It is thought that the binding of CstF to DSE is made stronger by CPSF-CstF
interaction (48). The nuclear magnetic resonance (NMR) structure of RRM shows that the RRM contains
a binding pocket that is specific for binding to UU dinucleotide, while the rest of the RRM is more flexible
and can accommodate a greater range of sequences (52). The specificity of the RRM pocket and the
flexibility of the RRM outside of that pocket, allow RRM to bind variety of both GU- and U-rich sequences,
and discriminate against all other RNA sequences. As is the case in mammals, the yeast homolog,
RNA15, has the RRM that binds to GU-and U-rich sequences (53).
A paralog of CstF64, known as CstF64 tau is abundant in testis and is thought to be related to
high incidence of APA during spermatogenesis (54). However, others have shown that CstF64 tau is
abundant in most tissues and is redundant to CstF64 (55).
While CstF64 is known to bind to U- and GU-rich sequences, SELEX experiments with purified
CstF complex showed selection for RNA rich in G, U, and C (49). This suggests that although the premRNA binding of CstF occurs through CstF64, CstF64 alone does not fully determine the binding
specificity of the CstF complex.
1.1.10 Protein-Protein Interactions of CstF
CstF64 is composed of RRM, hinge domain, a proline/glycine (Pro/Gly)-rich region, and a highly
conserved C-term domain (12). The function of Pro/Gly-rich region is not known but may mediate proteinprotein interactions with other 3’ processing proteins and/or regulators. The hinge domain binds CstF64 to
CstF77 and symplekin in a mutually exclusive manner (42). Pcf11 and transcription coactivator PC4/Sub1
bind to CstF64 through its C-terminal domain (56).
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RNA interference (RNAi) knockdown of CstF64 in HeLa cells leads to increase in protein levels of
CstF64 tau (55). This led to thinking that CstF64 tau is more broadly expressed and is functionally
redundant in respect to CstF64.
CstF77 holds the CPSF complex together and has strong interactions with CPSF160, CstF64,
and CstF50 (29). Biochemical and eventually structural studies revealed that CstF77 C-terminal HAT
domain functions in CstF77 self-dimerization (42, 51). Mutations in HAT domain of in yeast RNA14 disrupt
self-association of this protein and result in impaired 3’ cleavage and polyadenylation activities (57).
CstF77 structure also contains a Pro-rich C-terminal domain that binds to CstF64 N-terminal hinge region
(58). The same type of protein-protein interaction was observed in yeast, where C-terminal region of
RNA14 binds hinge domain of RNA15 (homolog of CstF64) to form a heterodimer (59). Binding between
the HAT domains of CstF77 dimer is thought to bridge two copies of CstF64, which bind to adjacent
DSEs of the pre-mRNA.
CstF50 is composed of N-terminal dimerization region and seven WD40 repeats at its C- terminal
domain (60). CstF50 proteins form homodimers through their dimerization regions (42). WD40 repeats
are involved in protein-protein interactions with CstF77. Dimerization domains of CstF50 and CstF77 are
responsible for hexamer formation of the CstF. Through its association with the BRCA1-BARD1 complex,
WD40 is also involved in inhibition of 3’ processing during DNA damage response (61). Additionally,
CstF50 binds to RNAP II CTD and is therefore thought to be involved in recruiting CstF to the
transcription elongation complex (62). There is no yeast homolog for CstF50 (12).
1.1.11 CFIm
CFIm is engaged in RNA binding and is required for 3’ cleavage but not for the poly(A) tail
addition (12). CFIm is comprised of CFIm25 and one of the following structurally related proteins,
CFIm68, CFIm59, or CFIm72 (63). CFIm functions as a heterotetramer, where two copies of CFIm25 and
two copies of either CFIm68, CFIm59, or CFIm72 make up the CFIm protein complex (64). CFIm does
not have a well-defined yeast homolog (1).
1.1.12 CFIm-RNA Interactions
CFIm has a direct role in recognition of the 3’ cleavage and polyadenylation site.
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All of CFIm subunits have RNA-binding motifs and are known to cross-link to pre-mRNA. CFIm
heterotetramer (e.g., CFIm252/CFIm682) binds to two UGUA elements located upstream of AAUAAA
element (64). The two UGUA upstream cis elements are simultaneously and specifically bound by two
CFIm25 proteins. The heterotetramer is formed through the RRM of each CFIm68 protein interacting with
both CFIm25 proteins simultaneously. Besides participating in protein-protein interactions, the RRM of
CFIm68 can also bind to pre-mRNA but only in presence of CFIm25. CFIm25 contains Nudix domain as
its central domain (65). The Nudix superfamily is common to all organisms and the proteins that contain
this domain are usually pyrophosphohydrolase proteins. However, CFIm25 is somewhat different from
other Nudix-containing proteins, in that its Nudix domain is lacking two key glutamate residues used for
metal coordination and nucleotide catalysis by the proteins of this superfamily (65). Neither presence of
metal ions nor catalysis were detected in CFIm25. Instead Nudix domain of CFIm25 was determined to
function in binding to UGUA and CFIm68 protein. Hydrogen bonding establishes most interactions
between the RNA and the CFIm25 protein. Also, Watson-Crick/sugar-edge base interactions of the RNA
confer specificity to RNA-CFIm25 binding (66). Two copies of CFIm25 protein bind two UGUA elements in
the antiparallel fashion. This type of RNA-binding results in the RNA looping, while the looping part of the
RNA (i.e., between the UGUA elements) is probably bound to the RRM of the CFIm68 (64). The RNAlooping through CFIm heterotetramer is recognized as a possible mechanism for APA site selection.
RNAi CFIm25 knockdown experiments show that reduction in CFIm25 protein leads to increases
in upstream poly(A) site usage within the pre-mRNAs with distinct upstream and downstream poly(A)
sites (67). Similarly, RNAi knockdown of CFIm68 resulted in induction of the 3’ processing at the
upstream poly(A) site (68). From the knockdown experiments it is clear that the pre-mRNA-binding of
CFIm is important for determining the APA site selection, however, the mechanism of APA site selection
and the role of CFIm within that mechanism remain to be determined.
Besides participating in recognition of the canonical 3’ cleavage/polyadenylation site, CFIm is
also capable of recognizing non-canonical 3’ processing sites that lack AAUAAA element but contain
UGUA sequences. In the case of 3’ processing at the non-canonical cleavage sites, CFIm functions as a
main RNA-binding factor that then recruits CPSF and PAP (69).
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1.1.13 Protein-Protein Interactions of CFIm
The C-terminal RS domain of CFIm68 contains alternating arginine and serine residues, and is
similar to the SR proteins involved in RNA splicing. The activity of splicing proteins is regulated through
phosphorylation of their C-terminal SR domains (70). Since like the splicing proteins, CFIm68 also has
the C-terminal RS domain, it may be that CFIm68 activity is regulated by phosphorylation. In this light,
CFIm68 protein becomes the best candidate for our phosphor-cleavage factor. CFIm68 has been shown
to co-purify with the spliceosome proteins (71, 72). The structure of CFIm68 and its protein-protein
interactions suggest that CFIm68 may be involved in coordinating splicing to the 3’ processing.
As mentioned earlier CFIm is a heterotetramer of two CFIm25 subunits and two subunits of either
CFIm68, CFIm59, or CFIm72. CFIm59 and CFIm68 are paralogs, while CFIm72 is an isoform of CFIm68
(73). CFIm25/CFIm68 is the most extensively studied CFIm heterotetramer. Each of the two CFIm68
subunits interacts with both subunits of the CFIm25 dimer by binding to the opposite sides of the dimer
(64). Interactions between CFIm68 and CFIm25 enhance the CFIm68 binding to pre-mRNA (74).
Chromatin immunoprecipitation (ChIP) analysis shows that CPSF, CstF, and CFIm are recruited
to pre-mRNA early on in transcription (69). CFIm facilitates CPSF-RNA binding, which in turn stabilizes
the binding of CPSF to pre-mRNA (63). CFIm25 interacts with PAP and PABPN1 proteins (74) and
possibly functions together with Fip1 of CPSF to recruit PAP to the 3’processing complex (74, 75).
1.1.14 CFIIm
CFIIm is the least characterized 3’ processing factor. CFIIm is made up of several subunits. While
other proteins at least partially separate from the CFIIm activity, Clp1 and Pcf11 are the only two subunits
that consistently co-purify with CFIIm activity on all chromatography columns (76). Clp1 and Pcf11 are
thought to be required for 3’ cleavage, however these proteins may not be the only CFIIm proteins
necessary for cleavage. In yeast, homologs of Clp1 and Pcf11 are required for 3’ processing and make up
yeast CFIA complex. CFIA is composed of Clp1 and Pcf11 subunits together with yeast homologs of
CstF77 (RNA14) and CstF64 (RNA15) (77).
In yeast, Pcf11 makes contact with all subunits of CFIA factor and RNAP II CTD (78). The Nterminal domain of Pcf11 is composed of eight α-helices and binds to both phosphorylated and
unphosphorylated states of RNAP II CTD. This binding is not required for 3’ processing, however it is
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necessary for transcription termination. The N-terminal domain of Pcf11 is followed by 20 glutamine
restudies, which link its N-terminal to its central RNA14-RNA15-binding domain (79). Finally, the central
domain is followed by a region where two zinc finger domains flank Clp1-binding region. In yeast, the role
of Pcf11 is to maintain CFIA complex and to mediate interactions between the 3’ processing factors.
Human Pcf11 is twice as large as its yeast homolog and the two homologs are similar in
sequence only at their N-terminal domains (76). However, as in yeast, knockdown of human Pcf11 leads
to defects in both 3’ processing and transcription termination (80).
Yeast Clp1 contains the ATP/GTP-binding domain as its central domain (76). This domain is
known as Walker A motif and is normally involved in ATP hydrolysis. However, in yeast Clp1, this domain
is capable of binding ATP without hydrolyzing it (81). From genetic, biochemical, and structural studies it
is known that mutations in this ATP-binding site lead to loss of Clp1-Pcf11 binding and disruptions in 3’
processing and transcription termination, although ATP may still be able to bind to Clp1 (82-84).
Primary sequences and structures of human and yeast Clp1 proteins are similar, however, human
Clp1, unlike its yeast homolog, functions as 5’-OH kinase of polynucleotides (85). The kinase activity of
human Clp1 has not been implicated in 3’ processing. In the 3’ processing the most likely role of Clp1 is to
maintain protein-protein interactions, mainly between CPSF and CFIm (76).
In a study where purification of CFIIm and its separation into CFIImA and another, stimulatory but
non-essential fraction, CFIImB, was accomplished via seven chromatography steps, CFIImA was
determined upon in vitro reconstitution of cleavage to have high 3’ cleavage activity and contained more
than 15 polypeptides (76). Clp1 was part of CFIImA and essential for 3’ cleavage activity. Pcf11, CFIm,
U2AF and TFIIH p89 co-IPed with Clp1 from CFIImA fraction. This study demonstrates that CFIm forms a
tight protein complex with CFIIm, splicing and transcription proteins. This same study found that Clp1
interacts directly with CPSF100 and CFIm (CFIm25, CFIm68, CFIm59, and/or CFIm72). The results of
this work show that CFIIm makes contact with both CFIm and CPSF. CFIIm forms protein-protein
interactions between the three factors and improves the overall stability of the 3’ processing protein
complex.
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1.1.15 Symplekin
Symplekin and its yeast homolog, Pta1, are part of 3’ processing complex (42). The two proteins
share weak sequence similarity, however both appear to function as scaffolding proteins. Pta1 is known to
interact with Ysh1 (CPSF73), Ydh1 (CPSF100), Fip1, Pcf11, Pap1 (PAP), and the RNAP II CTD
phosphatase Ssu72, hence Pta1 functions as a scaffolding protein (12).
In 3’ processing, symplekin competes with CstF77 for binding to the hinge region of CstF64 (42).
Besides its competitive binding to CstF64, in this same study, symplekin was also found to co-IP with
CstF64, CPSF100 and CPSF160 via anti-CstF64 antibody. Combined together the results from this study
show that symplekin is part CPSF-CstF complex and most likely functions as a scaffolding protein that
helps to bridge and assemble the CPSF-CstF complex.
Symplekin may also bind to CPSF73. Symplekin association with CPSF73, CPSF100, and
CPSF160 forms a protein complex core that functions in both general and histone pre-mRNA 3’
processing (40).
1.1.16 RNAP II CTD
With few exceptions, protein-encoding genes are transcribed by RNAP II. There are proteinprotein interactions between the components of pre-mRNA processing machinery and the CTD of RNAP
II (86). The CTD of RNAP II functions as a platform for protein complex assembly of the 3’ processing
factors and also stimulates their activities. Both, in vivo and in vitro, CTD is required for 3’ cleavage
reaction (87), although, its exact function in 3’ processing is not known. The main posttranslational
modifications (PTM) are phosphorylation/dephosphorylation states of the CTD and the cis-trans
isomerization of prolyl peptide bonds (88).
1.1.17 PAP
In 3’ processing, once the pre-mRNA is 3’ cleaved, PAP is then responsible for synthesizing a
~200 poly(A) tail. PAP is required for cleavage of most but not all pre-mRNAs (20). By itself PAP has low
polymerization activity and needs CPSF to stimulate its activity by specifying the AAUAAA site (29). From
N- to C-terminal, human PAP consists of catalytic, central, RNA-binding, and serine/threonine (S/T)-rich
domains. Crystal structure of bovine α-PAP in complex with 3’dATP demonstrates that this ATP analog
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and RNA substrate (poly(A)) bind to the protein’s open central cleft that is encompassed by catalytic,
central and RNA-binding domains (89). The adenine base and the phosphate tale of the nucleotide are
shown to bind to the amino acids of the central domain.
Primary sequence and secondary structure of PAP are mostly conserved from yeast to humans
(90). The C-terminal of only vertebrate PAP contains extra ~20 kD region, or the S/T-rich region that has
been established as dispensable for PAP activity. Instead, the serines and threonines of this region are
subject to a variety of activity modulating PTMs, such as phosphorylation (91), acetylation (92),
sumoylation (93), and PARylation (94).
Mammalian PAP have direct but weak binding to CPSF160 (29). Free CPSF160 has a dominantnegative effect on both specific and nonspecific polyadenylation. It may be that this inhibition is an
unusual effect that results from the free-state of CPSF160. However, since polyadenylation without CPSF
can proceed several adenosines beyond ~200 nt, it could also be that CPSF through contact between
CPSF160 and PAP is regulating the synthesis and therefore the length of the poly(A) tail.
Also, PAP has been shown to interact with CFIm25 (74). And in yeast, Pap1 has its N-terminal
domain in contact with Pta1 (symplekin) and Yhh1 (CPSF160) (95), while the CTD interacts with Fip1.
1.1.18 PABPN1
For the second part of the 3’ processing reaction, CPSF, PAP, and PABPN1 are required for
efficient poly(A) synthesis in vitro (96, 97). Besides being involved in poly(A) synthesis, RNAi knockdown
of PABPN1 showed that deficit of PABPN1 leads to shortening of the mRNA 3’ untranslated region, in
other words, results in changes in APA expression profiles (98).
Both CPSF and PABPN1 are required for recruiting PAP to RNA and for good processivity of
PAP, meaning that PAP does not dissociate from the RNA until a full ~200 nt poly(A) tail is synthesized.
By binding to ~10 nt poly(A) sequence, PABPN1 proteins are thought to coat the length of the poly(A) tail
and in the process form a linear filament with 21 nm diameter (99).
1.1.19 Conclusion
All factors appear to be interconnected, with major direct mammalian protein-protein interactions
occurring between CstF (77k D) and CPSF (160 kD and Fip1); CPSF (100 kD) and CFIIm (Clp1); CFIIm
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(Clp1) and CFIm; CFIm25 and PAP; PAP and CPSF160 and Fip1; PAP and PABPN1; symplekin and
CstF64 (for summary see Table 1). Hence, the 3’ protein factors are highly connected with each other.
Proteins within the CstF appear to form a unified and stable complex, both CstF64 and CstF50 are bound
to CstF77. CPSF complex is thought to form two major subcomplexes mCF (CPSF73, CPSF100, and
symplekin) and mPSF (Fip1, CPSF160, Wdr33, and CPSF30). The most current and general model for
recognition of the 3’ processing site is that mPSF recognizes the upstream U-rich and AAUAAA cis
elements, while mCF recognizes the cleavage site and carries out the 3’ cleavage activity (Fig 1B) (41).

Table 1. Summary of 3’ processing factor function.
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1.2

ATP Function in Cellular Processes

1.2.1

Introduction
From previous studies we knew that ATP is required for 3’ cleavage of Ad2L3 pre-mRNA

substrate, but not for the SV40L substrate (14). In its ATP requirement for the in vitro 3’ cleavage, the
Ad2L3 substrate was considered to be representative of most pre-mRNAs. This suggested that ATP
might play an important function in 3’ cleavage. Our goal was to identify the role of ATP and its
mechanism of function in the in vitro 3’ cleavage reaction. To achieve this we used ATP and some of its
analogs, which mainly were ApCpp, AppCp, AppNp, 3’ dATP, and 2’ dATP (Fig 2).

Figure 2. Overview of ATP analogs and a model for the effect of ATP concentration on the in vitro
3’ cleavage reaction. Created by Dr. Kevin Ryan.
We used these analogs to see if any of them could stimulate or inhibit the in vitro 3’ cleavage
activity. One possible mechanism of action for ATP is as a phosphoryl group donor for protein
phosphorylation by a kinase enzyme. In such a case, it could be hypothesized that the β-γ
phosphodiester bond of the ATP would be hydrolyzed and γ -phosphate used to phosphorylate a target
protein. This phosphorylation would then stimulate the 3’ cleavage activity. The three compounds, ApCpp
and AppCp as well as AppNp, are non-hydrolyzable between α- and β-phosphates and β- and γphosphates, respectively. Expressly, AppCp and AppNp were used to see if lack of β-γ bond hydrolysis
could inhibit the 3’ cleavage reaction. In case 3’ cleavage is inhibited with these substrates then it is likely
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that ATP is a kinase substrate. However, in the case of an opposing result where 3’ cleavage takes place
in presence of one of the non-hydrolyzable analogs, the conclusion would then be that instead of
functioning as a kinase substrate, ATP might be hydrolysis-independent and possibly functions as a
protein-binding cofactor. ATP- and analog-containing in vitro 3’ cleavage reactions were carried out by
recombining the DEAE-fractionated 3’ processing factors (13). Each reaction contained ATP or one of its
analogs, in combination with CPSF, CstF, CFm, and PAP.
Previous work on the ATP dependence of the Ad2L3 substrate (100) showed that ATP stimulates
cleavage at low mM concentrations, and inhibits cleavage at higher concentrations. Thus, pre-mRNA
cleavage may have sensors of ATP concentration built into the ensemble of the cleavage factors (Fig 2).
When ATP is too low or too high, something is wrong in a cell and it is not advantageous to cleave and
polyadenylate mRNA. Normal ATP concentrations permit and even stimulate normal 3' processing. In my
work, I have sought to identify the cleavage factor responsible for permitting cleavage to proceed. The
inhibitory circuit factor is likely the CFIm25 factor; ATP binds the CFIm25 Nudix domain which also binds
the common UGUA motif found in most pre-mRNA. Displacement of the RNA by ATP likely is responsible
for inhibiting cleavage at high ATP concentrations.
In the next few subsections we describe the various functions of ATP molecule inside and outside
of the cell. We list some well know examples of ATP as an extracellular signaling molecule, as well as
examples of how its concentrations within the cell can stimulate and inhibit cellular processes. Finally, we
give examples of ATP as a protein-binding cofactor that does not require hydrolysis of any of its
phosphodiester bonds.
1.2.2

ATP as Extracellular Signaling Molecule
It is generally recognized that cytoplasmic ATP concentration is 3-10 mM, while extracellular

ATP, under basal conditions is approximately 10 nM (101). Once ATP is generated inside the cell via
oxidative-phosphorylation it would then exit the cell down its concentration gradient most likely through
nucleotide transporter (101). Once in the extracellular environment, ATP is rapidly degraded to ADP,
AMP, and adenosine. Due to being susceptible to rapid degradation by the extracellular enzymes, ATP is
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thought of as a local signaling molecule that affects either its own receptors (autocrine) or those of the
neighboring cells (paracrine).
Thus, ATP has been documented as both autocrine and paracrine extracellular signaling
molecule. Once released from the cell, ATP binds to extracellular purinergic receptors, such as P2Y and
P2X. There is also a P1 class of purinergic receptors and these receptor bind to adenosine molecules,
while, P2 receptors are thought to bind to ATP, ADP, UTP, and UDP. The P2X receptors are ATP-gated
calcium-permeable channels that can be modulated by extracellular Ca2+, Na+, Mg2+, H+ and metal ions
(102). The P2Y receptors, with exception of some receptors, bind to G proteins and phospholipases to
increase free calcium concentration within the cell (103). Both, P2Y and P2X, receptor types increase free
intracellular calcium, which in turn triggers release to and retention of ions outside of the epithelial cells.
This contributes to extracellular retention of water, which is defective in cystic fibrosis. Extracellular ATP
release and signaling has been implicated in altering a number of signaling pathways in the epithelial
cells. ATP is mainly known as an extracellular signaling molecule.
1.2.3

Cellular ATP Concentration as a Signaling Mechanism within the Cell
As discussed above, the idea that ATP functions extracellularly - by binding to purinergic

receptors - has been documented in several studies. However, the ATP molecule is also known to
function in intracellular signaling, where it serves as a kinase substrate that gives up its γ-phosphate to
phosphorylate a protein. Kinase signaling in turn stimulates and inhibits numerous other signaling
pathways. Additionally, ATP is less known as an intracellular signaling molecule of its own, that is
signaling without being hydrolyzed in the process. Even so, there are some examples in which
intracellular ATP concentration appears to regulate molecular functions of the cell, and in other instances
ATP serves as a hydrolysis-independent protein-binding cofactor in the protein complex assembly.
One example (104) of ATP as intracellular signaling molecule is in the case of protease activation
which is either induced or inhibited depending on cellular ATP concentration. At its basal physiological
levels, in the low millimolar range, the intracellular ATP has been shown to negatively buffer proteasome
activation in vitro. Inversely, lowering of the cellular ATP concentration to 50-100 µM, usually as a result
of cellular stress, stimulates proteasome activation in vitro. Taken together, the results of this study show

18

that the intracellular ATP concentration dictates proteasome activity. The precise way in which ATP levels
regulate protease activity is not known and could be direct or indirect.
In another example (105), intracellular ATP was shown to inhibit TRPC5 ion channels. TRPC5 is
a receptor potentiation ion (Ca2+) channel that is mainly located in brain and heart tissues. Since TRPC5
channels are highly permeable to Ca2+ ions, prolonged stimulation of these channels can lead to excess
of Ca2+ in the cell and result in Ca2+-induced cell death. Cellular ATP concentrations were increased using
cellular profusion via patch clamp mechanism, which was also used to record the resulting decrease in
TRPC5 currents. Profusion of ADP or control solution had no effect, whereas profusion of ATP, or its nonhydrolyzable analog AppNp considerably reduced TRPC5 currents.
Since increased intracellular ATP levels were found to inhibit calcium levels, it was concluded that
ATP helps to maintain TRPC5 channel activity. Using AppNp revealed that ATP has structural specificity
and therefore, rather than having a phosphorylation-mediated effect, it may bind directly to either TRPC5
channel or another protein that regulates this channel.
Additional example of cellular signaling via the intracellular ATP concentration was found in
chemoresistant colon cancer cells (106). The human colon cancer cell lines with acquired
chemoresistance were shown to have elevated levels of intracellular ATP, as well as upregulation of
aerobic glycolysis and HIF-1α protein levels. Acquired chemoresistance of these cells correlates with
increased ATP levels, while depleting ATP rendered them sensitive to chemotherapeutic reagents.
Increased ATP levels and upregulation of aerobic glycolysis indicate that chemoresistant cells need
increased amounts of ATP to survive the stress from chemotherapeutic reagents. The major regulator of
glycolysis is HIF-1α. Introducing even more ATP into these cancer cells reduced the already upregulated
expression of HIF-1α protein. Taken together, these results shows that intracellular ATP concentration
can regulate protein expression levels and drug resistant phenotype.
1.2.4

ATP as Protein Binding Cofactor
ATP has also been shown to act as a protein cofactor in the assembly of the proteasome

complex (107). The 26S proteasome is composed of two large multisubunit complexes, the 20S and the
19S subcomplexes. The 20S protein complex consists of four stacked heptameric rings, the two inner
rings contain protease subunits. The 19S subcomplex is a proteasome regulator that itself does not have
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a protease function but consists of six ATPases. It binds to the outer rings of 20S, and hydrolyzes ATP for
various functions of 26S proteasome. The assembly of 26S from 20S and 19S has been shown to require
ATP binding without ATP hydrolysis. Non-hydrolyzable ATP analogs, ATPγS and AppNp, replaced ATP
in 26S assembly. Even though, the protein complex assembly requires ATP without requiring its
hydrolysis, this step is also coupled to ATP-hydrolysis dependent 26S processes, such as protein
deubiquitination and degradation. That is ATP is eventually hydrolyzed in the steps following 26S
assembly. The results of this work shows that an intact ATP molecule can function as a protein binding
cofactor to carry out protein complex assembly.
Yeast nonsense mediated mRNA decay (NMD) is another example of when ATP binding to a
protein, independent of ATP hydrolysis, is required for activity of that protein (108). There are two main
consecutive steps to NMD, translation termination and nonsense-mediated mRNA decay. Translation is
terminated by ATP-bound Upf1p at the premature termination codon. This Upf1p-ATP binding prevents
Upf1p from interacting with RNA, which helps Upf1p to stay bound to the ribosome until translation
termination is completed. Once this step is completed, then ATP can be hydrolyzed by ATPase of Upf1p
to activate mRNA decay.
Upf1p-ATP binding that prevents Upf1p-RNA interaction, is critical for the translation termination
step. ATP has been shown to bind to mutant Upf1p that lacks helicase and ATPase activities (i.e., ATP
hydrolysis) and promote its dissociation from RNA, thus promoting translation termination in absence of
ATPase activity. Besides the use of mutant Upf1p, a non-hydrolyzable ATP analog, ATPγS, has also
been shown to bind to Upf1p and promote its dissociation from RNA, hence demonstrating that nonhydrolyzable analog of ATP can replace ATP to foster translation termination step. This study
demonstrates that in absence of ATP hydrolysis, the intact ATP molecule enhances function of Upf1p in
translation termination step, most likely through altering Upf1p protein conformation. Hence, ATP is a
functional protein binding cofactor in the NMD.
While studying the ATP effects on the various cellular processes, it is also important to consider
the cellular concentrations of ATP and dATP. The most recent study of HeLa subcellular ATP
concentrations showed that nucleus and cytoplasm have similar ATP levels, while unexpectedly
mitochondria has ATP levels lower than those of cytoplasm or nucleus (109). It is generally thought that
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cytosolic ATP levels range from 3 to 10 mM (101), while the cellular concentration of dATP during Sphase is 60 µM (110).
1.2.5

Conclusion
In summary, ATP has been well documented as the extracellular signaling molecule and a part of

kinase signaling pathways. However, less is known of ATP as a hydrolysis-independent protein-binding
cofactor and of the mechanisms through which changing intracellular ATP concentrations regulate other
cellular processes.
Basal intracellular ATP concentration has been observed to function as a proteasome inhibitor
and a regulator of calcium transport. Significant decrease in ATP concentration of the cell can lead to
activation of the either process and possibly induce cell death. On the other hand, in chemoresistant
cancer cells, the elevated ATP levels help these cells resist treatment with chemotherapeutic reagents.
The changing ATP levels appear to regulate cellular processes and as a result determine cell fate,
however, their exact mechanisms of action in regulating these processes are not yet known.
In short, ATP has been documented as a hydrolysis-independent protein cofactor in TRPC5mediated ion transport, 26S proteasome assembly, and translation termination of NMD. Cellular
concentration of ATP constrains TRPC5 channel transport. Although this process appears to occur in
absence of ATP hydrolysis, the unknown protein to which ATP binds can be imagined to eventually carry
out ATP hydrolysis as a step in a process downstream of the TRPC5 channels. The ATP function, in 26S
proteasome assembly and in translation termination step of NMD, is clearly to be that of hydrolysisindependent protein binding cofactor. That is independent of its hydrolysis and through binding to a
protein, ATP molecule is capable of either enhancing or initiating a step in a molecular mechanism. Also,
one of the studies, assembly of the proteasome complex, shows that after inducing one step of a
molecular mechanism, ATP is later hydrolyzed by the next step of that same mechanism. Therefore, it
appears that within this one molecular event, the protein cofactor property of the ATP is coupled to its
eventual hydrolysis in the subsequent step of that molecular mechanism. In our case of 3’ pre-mRNA
cleavage, whether ATP is hydrolyzed or coupled to eventual ATP-hydrolysis is discussed in the results
sections.
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1.3

Use of ATP Analogs in In Vitro 3’-End Processing Reaction

1.3.1

Introduction
Several ATP analogs have been used on a number of pre-mRNA substrates in in vitro 3'

processing reactions to study both the 3’ cleavage and polyadenylation reactions. Initially ATP analogs
were used to help determine best conditions for the in vitro 3' processing reaction and eventually as
compounds that could aid in understanding the functions of this mechanism and the patterns of its
protein-protein interactions.
In the earlier studies of 3' processing, dATP, ApCpp, and AppCp were used to understand the
mechanistic steps and to obtain optimal conditions for the in vitro assays, and in the process obtained
some understanding of how ATP analogs affect 3’ cleavage and polyadenylation reactions (100). Some of
the specific cis sequencing, such as AAUAAA and DSEs were already identified as necessary for
specifying the reaction. However, a number of conditions for this in vitro reaction remained unexamined.
Moore and Sharp (100) study verified the accuracy of the Ad2L3 pre-mRNA substrate in in vitro cleavage
and polyadenylation steps by confirming that sequences of the in vitro and in vivo products were exactly
the same. They also hypothesized that the ATP molecule may play an additional role in 3’ processing
besides that of substrate in poly(A) tail synthesis. The ATP molecule became important when this group
showed that ATP appeared to stimulate 3’ processing, with best results occurring at 1 mM ATP. The little
to no cleavage of Ad2L3 substrate was seen in absence of ATP. ATP was proposed to act as an energy
supplier for 3’ cleavage reaction. A number of structural ATP analogs were also tested in 3’
cleavage/polyadenylation reaction. In the same study, Moore and Sharp (100) showed that 3’dATP and
ApCpp stimulated cleavage of Ad2L3 precursor while inhibiting poly(A) addition at the same time. From
such results it was concluded that 3’ cleavage and polyadenylation can be mechanistically uncoupled in
vitro. Another analog, AppCp, with non-hydrolyzable β-γ bond produced similar amount of 3’ cleavage
product as ATP. However, the poly(A) tail synthesized was much shorter when AppCp was used in place
of ATP. In summary, this study established that besides being a substrate for poly(A) synthesis, the ATP
molecule may have an additional important role in in vitro and/or in vivo 3’ processing. This conclusion
was mainly supported by the results which showed that ATP was required to stimulate an efficient 3’
cleavage reaction.
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In another study, ATP and its analogs were used to identify the exact 3’ cleavage site on the
Ad2L3 RNA precursor (21). ApCpp and 3’ dATP were used in the same manner as in the study above
(100) that is to uncouple 3’ cleavage from polyadenylation. When used in place of ATP, these analogs
generated efficient 3’ cleavage. No 3’ cleavage occurred in the in vitro reactions in absence of ATP or its
analogs. The results of this study confirm the idea that ATP could be an essential 3’ cleavage reaction
cofactor.
In a later study, Moore, Skolnik, and Sharp examined the effects of ATP and its analogs on 3’
processing or more specifically 3’ processing complex assembly (111). This was done by incubating HeLa
NxT with Ad2L3 precursor RNA in absence of ATP, or in presence of either ATP or ApCpp. The
incubation mixture was then subjected to velocity sedimentation in a glycerol gradient. Gradient fractions
were collected and analyzed for presence of radioactively labeled RNA, which was later extracted and
characterized by gel electrophoresis. The results showed that without ATP most of the RNA was found in
32S fraction. This fraction contained intact precursor RNA only, which is consistent with previous results
showing that ATP is necessary for both cleavage and polyadenylation. Their results also showed that with
the addition of ATP, most of the RNA was in 50S fraction and that this RNA was a mixture of intact
precursor and polyadenylated RNA. When ApCpp was used in the reaction, again most of the RNA
precipitated in the 50S fraction. The 50S fraction under these conditions contained mostly the unreacted
precursor and a lesser amount of the 5’ upstream cleavage product. No polyadenylated RNA was
observed because ApCpp blocks poly(A) addition. Their conclusion was that in the 3’ processing, 50S
represents an intermediate that requires presence of ATP or ApCpp. The ability of ApCpp to both replace
ATP during 3’ cleavage and block polyadenylation was exploited to show that the formation of the 50S
intermediate complex does not depend on polyadenylation. Collectively, the results of this study show
that ATP is required for assembly of intermediate 3’ processing protein complex. Such an idea supports
the above mentioned conclusion that ATP is required for 3’ processing of Ad2L3 RNA precursor. By
showing that ATP is required for protein complex assembly, this study begins to explain the way in which
ATP may function in 3’ processing.
In yet another study, by Sperry and Berget, the role of ATP in 3’ cleavage was tested on simian
virus 40 early (SV40 early) pre-mRNA substrate (112). This substrate is different from Ad2L3 in that is
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contains two copies of the AAUAAA element, where the downstream one directs polyadenylation. When
SV40 early was assayed with and without ATP, it was discovered that ATP is required for correct
cleavage of this RNA substrate, while cleavage in absence of ATP produced a product that was 18 to 20
nt longer that the product generated by correct cleavage. It was also shown that ApCpp could replace
ATP to generate accurately cleaved product RNA. Since this alternative cleavage product had the same
3’ cleavage properties and requirements as the correct cleavage product, it was concluded that
alternative product is part of normal polyadenylation machinery or another RNA-processing event. The
paper finally concludes that ATP-dependent changes occur in the 3’ processing machinery that determine
the 3’ cleavage site. Overall, this paper shows that ATP has a significant effect on a 3’ cleavage of the
RNA substrate other than the Ad2L3 substrate. As mentioned above, SV40 early has distinctively
different sequences from those of Ad2L3 substrate. ATP is required for 3’ cleavage of both substrates,
however, the exact effects of ATP are different, which may be explained by the differences in pre-mRNA
substrate sequences. In short, this is yet another study that points to ATP as a functional component of 3’
cleavage, and in this case, 3’ cleavage of SV40 early RNA substrate.
The work of Zhang and Cole explores the roles of ATP and its analogs in 3’ processing of the premRNA substrate with the polyadenylation signal region of herpes simplex virus type 1 thymidine kinase
(tk) gene (113). This study found that tk substrate can be efficiently cleaved and polyadenylated in vitro.
The tk substrate has two copies of the AAUAAA element, where the upstream copy directs the 3’
processing. In the case of this substrate, ATP was required for 3’ cleavage and could be replaced by
either 3’ dATP or ApCpp. Negligible 3’ cleavage was detected when AppCp was used in place of ATP.
Besides establishing the roles of ATP and its analogs in 3’ cleavage of tk precursor, Zhang and Cole also
determined the roles of these compounds in 3’ protein complex formation. It was found that the formation
of the 3’ protein complex required AAUAAA sequence and presence of ATP, 3’dATP, ApCpp, or AppCp.
The 3’ protein complex does not form in absence of ATP or one of its analogs. As seen from this study,
another pre-mRNA precursor is shown to require ATP for its cleavage and protein complex assembly.
Ryner and Manley examined conditions required for 3’ cleavage reaction of pre-mRNA containing
SV40 early introns and poly(A) site (114). This substrate is 1,300 nt long as opposed to 264 nt long SV40
early substrate from Sperry and Berget (112) study mentioned above. Both substrates have the same
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polyadenylation signal regions. Their work showed that with the long RNA substrate, 3’ cleavage reaction
requires Mg2+ and is inhibited by ethylenediaminetetraacetic acid (EDTA). It was also shown that
spermidine could replace Mg2+ but could not induce 3’ cleavage in presence of EDTA. Besides Mg2+, ATP
was also required for 3’ cleavage of this substrate. The 3’ dATP and ApCpp were tested in 3’ cleavage in
presence of ATP. Such reactions showed that 3’ dATP inhibits cleavage, while ApCpp addition produces
no significant effect.
The longer SV40 early substrate differs from other in vitro used pre-mRNA substrates in that its 3’
cleavage reaction requires Mg2+ and is inhibited by EDTA. Another point of difference for 3’ cleavage
reaction of this substrate from all the other substrates is that in the case of SV40 early 3’ dATP inhibits
instead of stimulating 3’ cleavage. These differences in 3’ cleavage reaction requirements could be
attributable to the length of pre-mRNA substrate. It may be that the longer SV40 early substrate adopts a
complicated secondary structure that needs to be stabilized or destabilized by direct Mg 2+-binding before
3’ protein complex can form on the pre-mRNA. EDTA would probably have a role opposite to that of Mg2+.
Similarly, 3’ dATP could be affecting the secondary structure of this pre-mRNA in the way that is inhibitory
to 3’ cleavage reaction. In summary, the sequence and the length of pre-mRNA substrate may determine
the efficiency of 3’ cleavage reaction. However, ATP is still required for the 3’ cleavage of this substrate.
The study by Hirose and Manley set out to determine the roles of creatine phosphate (CP) and
ATP in in vitro 3’ cleavage reaction (14). Prior to this study, it was thought that CP serves as phosphate
donor to ADP to generate ATP and ATP in turn serves as energy donor for the in vitro 3’ cleavage
reaction. This group found that there is no phosphate transfer from CP; that ATP is not required for the in
vitro 3’ cleavage of SV40L; and that ATP significantly enhances in vitro 3’ cleavage of Ad2L3. This same
group also states that in 3’ cleavage, Ad2L3, not SV40L, is like to be more representative of most other
pre-mRNA substrates.

1.3.2

Conclusion
Most groups that used ATP and its analogs in in vitro polyadenylation reactions, did so to

establish reaction conditions or to uncouple cleavage from polyadenylation. A few groups used these
compounds to isolate and identify protein complex of the 3' processing. All the studies mentioned above
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showed that ATP significantly enhances the 3' cleavage of the following pre-mRNA substrates, Ad2L3,
SV40 early, tk RNA, and the longer form of SV40 early. For most substrates, ATP analogs, ApCpp and 3’
dATP, can replace ATP in 3' cleavage reaction, while inhibiting the poly(A) tail addition. Moore and Sharp
(100) showed that with AppCp a small amount of product with a short poly(A) tail is generated from the
Ad2L3 substrate, however, they did not sequence the product to confirm that it was properly cleaved;
instead it may have been a non-specific polyadenylation of the uncleaved substrate. In the case of tk
RNA substrate, although 3' protein complex formed with AppCp, this compound was not able to replace
ATP in stimulating 3' cleavage activity. The studies mentioned above do not identify the exact role of
AppCp analog in the 3’ cleavage reaction. The 3' dATP functioned in place of ATP to stimulate cleavage
with all pre-mRNA substrates except for the long version of SV40 early. The large size of this substrate is
thought to be responsible for the inhibitory effect of 3’ dATP on 3' cleavage activity. Overall, all of the
groups mentioned above, saw that ATP stimulated a significant increase in the 3’ cleavage efficiency and
was required for the formation of the 3’ protein complex on Ad2L3 and tk pre-mRNA substrates. Although
ApCpp, stimulated 3’ cleavage when used in place of ATP, its use in the in vitro 3’
cleavage/polyadenylation reaction was not as informative as those of 3’ dATP and AppCp.
In conclusion, ATP has a significant effect on the 3’ cleavage efficiency of most substrates, but
the way in which it stimulates the reaction is not clear.

1.4

Phosphorylation State of Proteins within the 3’ Processing Complex

1.4.1

Introduction
So far we discussed that ATP is important for the in vitro 3’ cleavage efficiency and that we

suspect role of ATP in 3’ cleavage is to stabilize the protein complex assembly either through transfer of
its terminal phosphate to some protein or to act as a protein-binding cofactor. In the following section we
discuss a somewhat different topic, the role protein phosphorylation in in vitro 3’ cleavage reaction.
Dephosphorylation of 3’ processing components is known to inhibit 3’ cleavage activity (13). Our goal is to
identify the 3’ processing proteins that are affected by dephosphorylation.
Several proteomic and some in vitro studies identified numerous PTMs of cleavage factors,
however, functions of these PTMs are not known. Proteomic studies conducted to identify
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phosphorylation (115), lysine acetylation, arginine methylation, and lysine sumoylation of 3’ mRNA
cleavage factor show that phosphorylation is the most common PTM found among the 3’ cleavage factors
(116). Previous in vitro studies in our lab, found that 3’ cleavage assay is strongly inhibited when a S/T
dephosphorylated HeLa NxT is used in the reaction (13). Figure 3 shows that susceptibility to
phosphatase was traced to the DEAE-sepharose CFm fraction of the 3’ cleavage protein complex. The
untreated CFm fraction was able to restore 3’ cleavage after treatment of the HeLa NxT with calf intestinal
phosphatase (CIP).

Figure 3. Susceptibility to phosphatase is traced to CFm factor. The 5’ and 3’ RNA fragments are
indicated on the sides of the gels and each lane is labeled at the bottom of the figure. Each reaction is a
reconstitution reaction from all three fractions CPSF, CstF, and CFm, All. Fractions above the brackets
are either treated (+) or not treated (-) with CIP and phosphatase is inactivated by EDTA before the other
two (untreated) fractions are added to reconstitute the reactions. Two substrates are used here, SV40L
and Ad2L3. Input (RNA substrate alone). Adapted from Ryan 2007.
Figure 3 shows that dephosphorylation of no other fraction but the CFm-containing fraction
inhibits the 3’ cleavage activity. Phosphorylation of the CFm factor may control the in vitro 3’ cleavage
reaction by initiating protein-protein interactions within the 3’ end protein complex or by enhancing the
stability of this protein complex.
A later study from our lab presented some more evidence for the role of phosphorylation in the 3’
cleavage reaction (117). In that study, it was shown that the S/T phosphatase inhibitors can activate the
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in vitro 3’ cleavage activity. S/T phosphatases are divided into three major superfamilies: PPP includes
PP1, PP2A, PP2B, PP4, PP5, and PP7; PPM is Mg2+/Mn2+-dependent and includes PP2C; and finally,
the DXDXT/V motif phosphatases act on RNAP II CTD (118).
The study listed above hypothesized that CP, which is normally required for the in vitro 3’
cleavage activity, may be mimicking a phosphor-amino acid and as a result competitively inhibiting a
native phosphatase that normally acted to suppress 3’ cleavage in vitro. A general S/T phosphatase
inhibitor, fluoride, was able to activate 3’ cleavage when used in place of CP. Inhibitor of each superfamily
was tested in 3’ cleavage reaction as a substitute for CP. All inhibitors failed to activate the reaction
except for the inhibitor of PPM superfamily. Although not a phosphatase inhibitor, phosphocholine was
also able to replace CP. Structural analogs of the PPM inhibitor and phosphocholine showed that in vitro
3’ cleavage is dependent on particular functional groups and on specific arrangement of those groups
within the activator molecule. The fact that the structural arrangements of the activator (i.e., PPM inhibitor)
were important to the 3’ cleavage outcome, implies that the activator may have a protein-binding site and
that CP could be functioning by binding to a phosphatase. However, the high concentrations of all small
molecule activators tested to date make unclear any physiological significance.
Since S/T phosphatase dephosphorylation of HeLa NxT inhibits in vitro 3' cleavage reaction,
while replacing CP with S/T phosphatase inhibitor stimulates the reaction, then it appears that
phosphorylation of 3’ processing proteins may be regulating the 3’ cleavage activity. However, it is not
clear where cleavage-related phosphorylation occurs and how it functions in determining the outcome of
the cleavage reaction. Phosphorylation-dependent cleavage was traced to the CFm fraction. Although
some proteins from this fraction have been characterized, some remain unidentified. Currently CFm is
viewed as a cis-binding protein complex. Since the dephosphorylation of a crudely fractionated protein
complex, CFm, results in loss of cleavage, the dephosphorylation effect on cleavage is likely to be via the
loss of phosphate from one or another type of complex-forming cleavage factor within a pre-cleavage
complex.
Reversible protein phosphorylation is implemented by a large number of kinases and
phosphatases (119). Protein phosphorylation is the most abundant molecular control mechanism. It
activates and inhibits enzymatic activity, protein-protein interactions, and determines protein
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conformations and their intracellular localization. Signal transduction is regulated and amplified by
phosphorylation. Phosphorylation of a protein confers it with new ion, salt bridge, and hydrogen bonding
interactions. In eukaryotes, reversible phosphorylation is mainly conducted on serine, threonine, and
tyrosine residues. Several posttranslational protein modifications have been identified for 3’ processing
proteins, while phosphorylation is the most common of these PTMs (116).
1.4.2

Posttranslational Modifications of 3’ Processing Proteins
The protein phosphorylation sites of the 3’ cleavage and polyadenylation factors were identified

through the use of phosphoproteomic mass spectroscopy (MS) screens. Most of the phosphorylation
sites were either on serine or threonine residues. From CPSF, only CPSF100, CPSF160 and Fip1
contained phosphorylation sites (115). In the epidermal growth factor (EGF) pretreated cells, these same
proteins had changed phosphorylation sites (120). Phosphorylation sites were not found on either the
CSPF30 or CPSF73. Fip1 had the greatest number of the phosphorylation sites. Most Fip1
phosphorylation sites cluster on the acidic N-terminal and the R-rich C-terminal domains.
From CstF, CstF77 had one phosphorylation site in its C-terminal region (120). For CstF64, four
phosphorylation sites were identified between its MEARA/G repeat domain and conserved C-terminal
region (120, 121). CstF50 was found to be phosphorylated at a C-terminal tyrosine residue but only in
lymphoma cell lines (122).
In CFIm, CFIm68 had only one phosphorylation site five residues after its RRM motif (121), but it
also had a RS domain, similar to that found in SR protein splicing factors, whose phosphorylation
regulates protein-protein interactions within the spliceosome. For CFIm59, seven phosphorylation sites
were detected. The phosphorylation sites of this protein: two phosphorylation sites N-terminal to its RRM
motif (123), two phosphorylation sites 33 nt beyond RRM region (124, 125), and two residues in the Cterminal RS region (120). Phosphorylation of one tyrosine residue of CFIm25 was discovered in two
cancer cell lines (122). No phosphorylation sites were identified on Clp1. Three different studies found
four phosphorylation sites on Pcf11 (115, 120, 126).
PAP is inhibited by phosphorylation of seven sites in its S/T-region during cell cycle progression
(91, 127). Proteomic studies identified only two phosphorylation sites in the S/T-region of PAP (115, 126).
Three phosphorylation sites have been identified at the C-terminus of symplekin. RNAP II CTD can
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become hyperphosphorylated (87), however, its phosphorylation state was shown to be dispensable for
the 3’ cleavage activity (128).
It should also be mentioned that PTMs other than phosphorylation can determine functions of the
3’ processing proteins. Lysine acetylation seems to play an important role for PAP and CFIm25.
Acetylation of both prevents them from interacting with each other and determines localization of PAP in
the cell (116). Arginine methylation of CFIm68 just before its Pro-rich region is predicted to regulate
CFIm68 interactions with its binding partners (129). Lysine sumoylation was found in CPSF73 and
symplekin (130). Symplekin sumoylation appears to be necessary for both 3’ cleavage and
polyadenylation. Overall, PTMs are important for regulation of 3’ protein complex assembly, cleavage and
polyadenylation.
1.4.3

Role of Phosphorylation in 3’ Protein Complex Assembly
The 3’ protein complex assembly is established through protein-protein interactions (PPI), which

in turn could be influenced by such PTM as phosphorylation (131). PPIs are involved in many functions of
the cell. Although, it is important to recognize that there is a spectrum of protein-protein binding affinities,
PPIs are usually characterized as either permanent or transient. The strength of interactions between
proteins determines their function. Overall, permanent PPIs are known to function in assembly of large
complexes as well as enzyme-inhibitor and antigen-antibody structures. While transient PPIs are more
representative of signaling pathways where protein activity is dynamic and under a tight temporal control
(132). Permanent interaction interfaces have more of conserved residues than transient interfaces and
also tend to be more hydrophobic, while transient interface sites are more polar. The size of permanent
interface is usually larger than that of a transient one.
Permanent PPIs are normally established through specific protein-binding domains such as HAT
domain of CstF77 or dimerization domain of CstF50, whereas proteins with transient PPIs undergo
dynamic conformational changes which in some cases are represented by disorder-to-order transitions.
Some proteins are able to switch between their interaction partners as is the case with the C-terminal
region of p53 (133, 134). This switching mechanism is operated by post translational modifications, one of
them is phosphorylation. One example of phosphorylation as a mechanism for protein-protein interaction
switching is in the case of p53-MDM2-USP7 pathway. Under stress conditions, MDM2-USP7 interaction
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is reduced via phosphorylation, the now free USP7 can bind and de-ubiquitinate p53 (135).
Phosphorylation is a dynamic PTM that could function as a switch mechanism in protein-protein binding.
Addition or removal of a phosphate to a protein residue can change that protein’s stability,
conformation, binding-affinities, and activity (136). Protein phosphorylation moderates the strength and
structural nature of protein-protein interactions and is therefore responsible for regulating many cellular
pathways and mechanisms. In such instances, where phosphorylation occurs at the binding surface, it
has direct effect on the strength of PPIs. In other instances, when phosphorylation occurs away from the
binding surface of the protein it may bring on conformational changes which then affect the PPIs. One
example of such long range conformational changes is of glycogen phosphorylase, where
phosphorylation induces structural rearrangements of hydrophobic residues which then trigger
conformational changes in the active site that result in activation of the protein (137). Another instance of
phosphorylation as determinant of protein-protein binding is when one protein recognizes and binds to a
phosphorylated serine/threonine or tyrosine domain of another protein and as a result alters its activation
(138).
Using computational methods to analyze large data of PPIs, one study found that phosphorylation
sites tend to be located on binding interfaces of heteroligomeric protein complexes and homooligomers
involved in weak transient PPIs (131). No association for phosphorylation sites and protein-binding
interfaces was found for permanent PPIs of homooligomers.
1.4.4

Conclusion
Overall, in our lab, it was previously found that dephosphorylation of HeLa NxT leads to inhibition

of cleavage. Phosphorylation-dependence of the 3’ cleavage reaction was traced to the DEAE-sepharose
purified CFm fraction, which is composed of CFIm and CFIIm factors. We have also shown that PPM
(serine/threonine) phosphatase inhibitors can replace CP to generate 3’ cleavage in vitro, though like CP,
high concentrations are needed. When mediated by partially purified cleavage factors (as opposed to
HeLa NxT) in vitro 3’ cleavage does not occur efficiently in the absence of CP. Hence, we concluded that
CP and PPM inhibitor function in a similar manner by either inhibiting a phosphatase or altering its or
another protein’s conformation. The inhibitory effect of dephosphorylation and stimulatory effect of
phosphatase inhibitor on 3’ cleavage suggest that cleavage factor phosphorylation plays a role in this
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reaction. Additionally, the most common posttranslational protein modification among the 3’ processing
factors is phosphorylation of either the serine or the threonine residues. Several of the 3’ proteins are
phosphorylated, while Fip1, PAP and CFIm59 are the most highly phosphorylated ones. Since
phosphorylation is significantly more likely to function via transient protein-protein interactions, we
suspect that the cleavage-related phosphorylation of CFm modifies either strong or weak transient
protein-protein interactions within complexes that form leading up to 3’ cleavage reaction. To understand
the role of phosphorylation in 3’ cleavage reaction, we set out to identify protein(s) with these cleavagespecific phosphorylation sites.
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CHAPTER TWO: What is the Role of ATP in 3’ pre-mRNA Cleavage?

2.1

Introduction
To test the effects of ATP and its analogs on in vitro 3’ cleavage, we employed two commonly

used pre-mRNA substrates, Ad2L3 and SV40L. ATP and PAP are required for the 3’ cleavage of Ad2L3
but not the SV40L substrate (14, 139). For 3’ cleavage of Ad2L3 pre-mRNA, reactions consisted of
DEAE-fractionated cleavage factors: CPSF, CstF, CFm, plus additional PAP protein. PAP protein was not
included in the reaction with the SV40L substrate, but some is present in the DEAE-purified CstF fraction.
To obtain the DEAE factors we would fractionate the HeLa NxT on the DEAE-sepharose column where
CstF and PAP would elute together, followed by CFm, and finally CPSF (13). These 3’ processing DEAEpurified factors can then be recombined in vitro to give 3’ cleavage and polyadenylation of a radioactively
labeled pre-mRNA substrate. The factors are partially purified and some proteins from splicing and
transcription could still be bound to and elute together with the DEAE factors. Other groups had purified
CFm factor further into CFIm and CFIIm factors, followed by purification of CFIIm into CFIImA (cleavage
specific activity) and CFIImB (cleavage stimulatory activity) (76). Purification of 3’ processing factors via
the DEAE column was sufficient enough for our purposes. Along with cleavage factors and other standard
3’ cleavage reaction components, described in Section 2.2.1, all reactions contained 50 mM CP and 2
mM EDTA. CP is required for efficient in vitro cleavage with either of the RNA substrates. However, its
exact role in 3’ processing is not known. When ATP is included in the 3’ processing reaction, EDTA is
used to uncouple 3’ cleavage from poly(A) addition by chelating Mg2+ of PAP and hence preventing PAP
from polymerizing the poly(A) tail (14).
The requirements and effects of ATP and some of its analogs in in vitro 3’ cleavage reaction were
previously examined for several RNA substrates (discussed in Section 1.3), however, the exact function
of ATP in cleavage remains undetermined.
Earlier investigations showed that ATP significantly enhances the 3’ cleavage activity of the
Ad2L3 RNA substrate (Fig 4). ATP analogs, ApCpp and 3’dATP, were found to replace this ATP
requirement, and uncouple cleavage from the polyadenylation reaction (21, 100).
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Figure 4. ATP has a positive effect on 3’ cleavage of
Ad2L3 substrate. M and Pre indicate size marker (in
nucleotides) and precursor RNA, respectively. 5’ and 3’
RNA cleavage products are indicated on the right side of the
gel. Lanes 1-4 contain increasing amounts of CP and no
ATP, while lanes 5-8 contain increasing amounts of CP and
1 mM ATP. All cleavage reactions were reconstituted from
CPSF, CstF, CFIIm, CFIM, and PAP. Adapted from Hirose
and Manley 1997.

Another ATP analog used in 3’ cleavage was AppCp. With Ad2L3 substrate, AppCp analog is
thought to give similar levels of cleaved and polyadenylated RNA as those produced with ATP (100).
However, in the case of tk RNA substrate, while ATP is required for cleavage of tk precursor RNA, AppCp
produces minimal levels of the cleavage product with this substrate (113). The ability of AppCp to have
effect on 3’ end cleavage of Ad2L3 RNA substrate indicates that AppCp may act in place of ATP, but the
cited references show contradicting results for the role of AppCp in in vitro 3’ cleavage reaction.

2.2

Experimental Procedures

2.2.1

Buffers and General Methods
Buffer D: 20 mM Na-HEPES, pH 7.9, 20% glycerol, 0.2 mM PMSF, 0.5 mM DTT, 0.2 mM EDTA,

50 mM ammonium sulfate; Buffer D10Glyc: Buffer D except 10% glycerol; His-Tag Native Lysis Buffer: 50
mM NaH2PO4 pH 8.0, 300 mM NaCl, 10 mM imidazole; His-Tag Native Wash Buffer: lysis buffer with 20
mM imidazole pH 8.0; His-Tag Elution Buffer: lysis buffer with 250 mM imidazole pH 8.0; SodiumChloride-Tris-EDTA (STE) Buffer: 10 mM Tris pH 8.0, 50 mM NaCl, 1 mM EDTA; Phosphate Buffer
Saline: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 pH 7.4.
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Protein concentrations of NxTs, cleavage factor purifications, wild-type (wt) and mutant (mut)
PAP protein purifications were determined using Bio-Rad Bradford protein assay with BSA (Roche) as the
standard.
2.2.2

Preparation of HeLa Cell NxT, CSF Fraction, and DEAE-Sepharose Cleavage Factors
Suspension prepared HeLa cell pellets were purchased from the National Cell Culture Center

(Biovest International). NxT was prepared as described in detail elsewhere (13). Cleavage factor activities
(CPSF, CstF, CFm) were fractionated from the NxT on a DEAE-sepharose column, ammonium sulfate
precipitated and dialyzed into Buffer D, as previously described (13).

Figure 5. Separation of NxT into two distinct fractions, CSF and PAP.
The CSF fraction was prepared as described by others with some minor modifications (13, 20).
Figure 5 demonstrates the overall process. At first, to prepare the 20-40 (NH4)2SO4 fraction, 0.114 g solid
(NH4)2SO4 was added per 1 ml of NxT at 4C. This was followed by pH neutralization with 1 µl of 1 M
NaOH per gram of (NH4)2SO4. After stirring on ice in a cold room for 30 min, the supernatant was
collected by centrifugation (16,500 rpm, 20 min, at 4C). 0.123 g of (NH4)2SO4 were added per 1 ml
supernatant and the mixture was stirred and centrifuged as described above. The precipitate was now
labeled as the 20-40 (NH4)2SO4 fraction. It was resuspended in the minimum volume of Buffer D, about 3
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ml. One ml of the 20-40 (NH4)2SO4 fraction (≈ 10 mg protein) was passed through a Superose 6 column
(10/300 GL, GE Healthcare) equilibrated with Buffer D containing 200 mM ammonium sulfate, and 0.5 ml
fractions were collected. Adjacent fractions were pooled and 0.37 g of solid (NH 4)2SO4 was added to each
tube. The tubes were gently agitated for 1 h at 4C followed by centrifugation (13,200 rpm, 20 min, at
4C). The precipitate was resuspended in 100 µl of Buffer D and dialyzed against the same buffer. Active
CSF fractions were identified using an in vitro cleavage assays with the SV40L substrate. PAP fractions,
eluting after CSF, were identified using a non-specific in vitro polyadenylation assay (supplemented with 1
mM Mn2+) (140).
Each nonspecific polyadenylation reaction was carried out with 2.5% of PVA, 0.1 µg of BSA, 20
mM CP, 1 mM MgCl2, 1 mM ATP, 3 nM Ad2L3 RNA, and one of the recombinant PAPs, either the wt or
mut PAPs. These reactions were carried out at 30C for 30 min.
2.2.3

The In Vitro 3’ pre-mRNA Cleavage Reaction
Uniformly α-32P-UTP-labeled RNA containing the SV40L and Ad2L3 poly(A) sites was made by in

vitro transcription from linearized plasmids pG3SVL-A and pG3L3-A, respectively (20). In vitro pre-mRNA
3’ cleavage reactions were carried out as previously described (13, 128) but without any phosphatase
pre-treatment. The total reaction volume was 12.5 µl and in place of NxT we used the following DEAEsepharose purified cleavage factor fractions: 0.9 µl of CPSF, 0.45 µl of CstF, 1.8 µl of CFm. HeLa PAP is
not retained on the DEAE column but elutes to some extent with CstF (76). However, to be sure that
sufficient PAP was present when the cleavage factor fractions were used, 5 – 50 ng of bacterially
expressed recombinant bovine PAPII (91) was included in the 3’ cleavage reactions. Water-dissolved
ATP or ATP analog was included at the final concentrations indicated on the figures. For the cleavage
reactions shown in Figure 12B, 5 µl of CSF (20) and 50 ng of either HeLa PAP, recombinant wild-type
PAPII or mutant PAPII were used per reaction.
The following 3’ cleavage reaction method was used for reactions in Figure 8. 3 µl of HeLa NxT
were dephosphorylated with 3 u of CIP for 35 min at 30C. This reaction contained 1.18 mM final
concentration of MgCl2. To stop dephosphorylation reaction, MgCl2 was quenched by adding EDTA to a
final concentration of 2 mM and then incubating it for 20 min at 30C. Mock dephosphorylation was done
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in the same manner as described above except CIP buffer was used instead of CIP enzyme. The
dephosphorylated NxT reaction was then pre-incubated for 15 min at 30C with the following components
(at their indicated final concentrations), 1.25 µg of tRNA, 2 mM 2’dATP, 1.6 mM DTT, 50 mM CP, 4 u of
RNase Inhibitor, 2.5 % PVA, 3 nM Ad2L3 and with either: 1: Buffer D alone, or 2: 4.2 mM MgCl2 and
0.138 mM ATP (final concentrations) and BSA, CPSF, CstF, or CFm, or 3: CFm with either 4.2 mM MgCl2
or 0.138 mM ATP. After 15 min, EDTA was added to the final concentration of 6 mM to each reaction to
quench all MgCl2 and the 3’ cleavage reactions were then allowed to incubate for another 105 min. The
rest was done as previously described (13).
2.2.4

Generating and Purifying Wild-Type and Mutant PAP Proteins
Primers for making the mutants of wild-type bovine PAP from pUK-wt His-PAP plasmid (gift of E.

Wahle) (19) were generated using the QuikChange Primer Design Program (Agilent Technologies).
K228A PAP mutant primers were Forward Primer 5’-TAACCCTGAGAGCT
ATCGCACTGTGGGCCAAACGCC-3’; Reverse Primer 3’-ATTGGGACTCTCGATAGCGTGACACCCGG
TTTGCGG-5’. Primers for Y237A PAP mutant were Forward Primer 5’-GGGCCAAACGCCACAA
CATCGCTTCCAATATATTAGGTTTCCT-3’; Reverse Primer 3’-CCCGGTTTGCGGTGTTGTAGCGAAGG
TTATATAATCCAAAGGA-5’. The double mutant (dm) was generated by using Y237A primers on the
K228A mutant plasmid. The PCR reactions and transformations were done as described in manual to the
Mutagenesis Kit (Agilent Technologies). The plasmid DNA was purified using a MiniPrep Kit (GenScript).
Altered regions of the mutant plasmids were verified by sequencing.
About 50 µl of competent E.coli BL21 (DE3) cells were transformed with 5 ng of either wt or one
of the mutPAPs. Each was then inoculated into 50 ml LB (100 µg/ml ampicillin) culture and grown
overnight. The overnight culture was inoculated into 4 L of LB/ampicillin culture and grown at 37 °C to
0.15 OD600, the temperature was then changed to 18°C and cells grown to 0.5 OD 600, at which point cells
were induced with 1 mM IPTG and grown at 18 °C for 18 h. Cells were harvested and stored at -80°C.
The pellet from 1 L of cell culture was resuspended in 32 ml of His-Tag Native Lysis Buffer, lysed two
times in a French Press, centrifuged at 10,000 rpm for 20 min at 4°C. The lysate was then incubated with
gentle agitation with 0.8 ml of drained volume Ni-NTA Agarose (Qiagen) beads for 2 h at 4 °C, transferred
to a column, washed 2 times with 4 ml of His-Tag Native Wash Buffer, and eluted with 4 consecutive 0.8
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ml aliquots of His-Tag Elution Buffer. All elutions were dialyzed twice against 1 L of Buffer D for 2 h at a
time, at 4°C.
2.2.5

pIRESneo3-Clp1-3XFlag Plasmid Construction
The expression vector pIRESneo3 (Clontech) was used to make pIRESneo3-Clp1-3XFlag

plasmid (Fig 6), which was then used to establish a Clp1-Flag protein expressing stable cell line. The
internal ribosome entry site of pIRESneo3 permits the translation of both, the gene of interest (Clp1
protein) and the Neomycin resistance gene, from a single mRNA, allowing for quick identification and
selection of stable transformed colonies. The expression plasmid was constructed as follows: The
pIRESneo3 plasmid was first modified with 3X-Flag insert. This was done by ligating the 85-nt dsDNA
oligonucleotide - coding for BamHI-XhoI-3xFlag-Stop-NotI - into the BamHI and NotI sites of pIRESneo3,
to form a plasmid named as pIRESneo3-3X-Flag. The ligated adaptor had the following complimentary
sequences, sense: 5’phosphoGATCCGCCTCGAGTGACTACAAAGACCATGACGGTGATTATAAAGATCATGATA
TCGATTACAAGGATGACGATGACAAGTAGGC-3’ and antisense: 5’phospho-GGCCGCCTACTTGTCA
TCGTCATCCTTGTAATCGATATCATGATCTTTATAATCACCGTCATGGTCTTTGTAGTCACTCGAGGC
G-3’. The ligation junctions of this plasmid were verified by sequencing. The protein coding portion of
pcDNA3.1-Clp1- Myc-His6 plasmid (previously made in our lab) was subcloned into the pIRESneo3-3XFlag plasmid. The pcDNA3.1-Clp1- Myc-His6 plasmid contained EcoRI restriction enzyme site just in front
of the Kozak-ATG element of the protein coding sequence and Xho I restriction enzyme site right after the
last amino acid of the Clp1 protein sequence. Therefore, EcoRI and XhoI restriction enzymes were
utilized to insert Clp1 proteins into the multiple cloning site (MCS) of pIRESneo3-3X-Flag plasmid, just in
front of the 3X-Flag sequence. The entire hClp1 open reading frame (ORF) and ligation junctions were
verified by sequencing. This plasmid, pIRESneo3-Clp1-3XFlag, was used to generate HeLa cell line with
stable expression of Clp1-Flag protein.
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Figure 6. Construction of pIRESneo3-Clp1, CFIm59, or CFIm68-3XFlag Plasmid. CMV stands for
human cytomegalovirus major immediate early promoter. MCS stands for multiple cloning site. IRES
identifies internal ribosome entry site. SV40 PolyA stands for SV40 early mRNA polyadenylation signal.
Restriction sites are in blue. The cDNA of CFm protein is in yellow. The EcoRI and XhoI restriction sites
were used to sub-clone the CFm proteins.
2.2.6

Stable-Cell-Line Establishment
A HeLa cell line stably expressing human Clp1-Flag protein was established as described below.

HeLa cells (JW36, ATCC) were grown in DMEM containing 10 % cosmic calf serum (CCS), 10 I.U./ml
penicillin and 10 µg/ml streptomycin (PS) at 5% CO2 and 37 ºC. A 4 cm 2 tissue culture plate well was
seeded with 2 x 105 of HeLa cells and grown overnight without PS. The next day cells were transfected
for 5 h with Lipofectamine 2000 (Life Technologies) and pIRESneo3-Clp1-3XFlag plasmid at 1:1 ratio
(µl/µg). The cell medium was then exchanged for fresh medium containing PS, and the cells were grown
overnight. The cells were then re-plated into a 10 cm diameter plate and incubated for 7 h. A water
solution of G418 disulfate antibiotic (RPI Corp.) (0.6mg/ml) was added and incubated with the cells for 2
days. The medium was again exchanged for fresh medium containing 1 mg/ml of G418 and replaced
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every five days. Single colonies became visible after two weeks of incubation at 37 C. Each colony was
isolated using a cloning cylinder (Corning), expanded, and tested for the presence of the Clp1-Flag
protein by western blotting with anti-FLAG antibody (Sigma-Aldrich).
2.2.7

Co-Immunoprecipitations
Two types of lysates were made. One lysate was made from HeLa cells (control) and the other

lysate was made from Clp1-Flag stably-expressing HeLa cells. The cells were detached with 0.05%
trypsin (Corning) for 5 min, washed in 1 ml of PBS, and pelleted. The cells were then snap frozen and
thawed to break the cell membrane. The cells were further lysed by gentle mixing in 50 µl of Buffer D 10Glyc
(per 10 cm plate of cell pellet) for 10 min. The cells were centrifuged for 10 min at 10,000 rpm and the
lysate concentrations were measured as in Section 2.2.1.
Four co-IPs were made, one contained HeLa cell lysate and the other three contained Clp1-Flag
HeLa cell lysate. All samples contained 200 µg of total protein per sample. To deplete ATP levels, 2 mM
glucose, 2.5 mM MgCl2 and 0.6 u hexokinase (final concentrations) were added to each sample and
incubated at 30 C for 10 min (14). Each sample was then incubated with the final EDTA concentration of
4.5 mM at 30 C for 10 min. 20 µl (drained beads volume) of Flag Affinity Beads (Sigma-Aldrich) were
added to each sample. No additional components were added to two of the samples, which were the
HeLa lysate (control) and one of the Clp1-Flag samples. 50 mM CP, 40 u RNase Inhibitor, and 3 nM
Ad2L3 RNA were added to the other two Clp1-Flag sample, which had either 4 mM ATP or 4 mM AppCp.
Buffer D10Glyc was used to bring the volumes of all four samples to 60 µl. All samples were incubated for 2
h at 4C with gentle rocking. The supernatants were collected from all co-IP samples. The beads were
washed three times with 200 µl of Buffer D10Glyc and eluted with 13 µl of Buffer D10Glyc plus 4 µg/µl FLAG
peptide (Sigma-Aldrich). Lysates, supernatants, and eluates were resolved on 10% SDS-PAGE and
probed by western blot with anti-Pcf11 (Proteintech) and anti-Clp1 (Abcam) antibodies.
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2.3

Results and Discussion

2.3.1

The Effects of ATP Analogs on In Vitro 3’ Cleavage Reaction
A number of the pre-mRNA substrates require ATP for the in vitro 3’ cleavage reaction. SV40L

pre-mRNA is the only known substrate, the 3’ cleavage of which is stimulated by but does not require
ATP to bring about a significant 3’ cleavage activity. With cleavage factors of very high purity ATP inhibits
SV40L cleavage at all concentrations, but especially above 1 mM (100). Ad2L3 was chosen as a
representative of ATP requiring substrates. To explore the role of ATP in in vitro cleavage reaction SV40L
and Ad2L3 RNA substrates were tested in the 3’ cleavage reactions with ATP and its analogs (Fig 7).
Substantial difference in relative cleavage (R.C.) levels of Ad2L3 substrate with H2O (10%)
verses ATP (100%), confirms in our hands that Ad2L3 requires ATP for its 3’ end processing (Fig 7A).
Figure 7D demonstrates that SV40L does not require ATP where R.C. for H 2O lane is at 40%. Although
addition of ATP to the reaction with SV40L results in 60% increase in R.C., the ATP addition effect is
more pronounced with the Ad2L3 substrate where ATP is essential for the 3’ cleavage activity. We do not
know why we observe that ATP slightly increases SV40L cleavage while others (14) have seen inhibition.
In the 3’ cleavage with Ad2L3 and tk RNA precursors, 3’dATP can be used in place of ATP to
stimulate cleavage, while at the same time inhibiting the polyadenylation reaction via 3’deoxy group of
this ATP analog (100, 113). In contrast to these substrates, 3’dATP inhibited 3’ cleavage of long version
of SV40 early precursor RNA (114). To further explore the effects of this and another compound on 3’
cleavage, 3’dATP and 2’dATP analogs were used in the 3’ cleavage reactions with the Ad2L3 substrate
RNA. Ad2L3, in reaction with ATP, has the R.C. of 100%, while its R.C. with 2’dATP and 3’dATP analogs
resulted in 146% and 44%, respectively (Fig 7A). 2’dATP appears to be more effective than ATP, while
3’dATP is less than half as effective as ATP. Our 3’ cleavage results for these two analogs indicate that
depending on the structure of their deoxyribose, these analogs can have either a weaker or a stronger
stimulatory effect on the 3’ cleavage activity. This evidence suggests that ATP and its analogs act on 3’
cleavage activity through their structural elements. Similar results were obtained for SV40L substrate in
the 3’ cleavage reactions with 2’dATP and 3’dATP analogs (Fig 7D).
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Figure 7. ATP analogs can either stimulate or inhibit 3’ cleavage activity. 5’ and 3’ RNA fragment
labels are on the left side of the gel. R.C. is 5’ fragment/ uncleaved RNA in percent is at the bottom of the
gel. Input lane is RNA alone. H2O lane is the 3’ cleavage reaction without ATP or any of its analogs. 3’
cleavage of Ad2L3 RNA substrate is in a reconstituted protein mix (CPSF, CstF, CFm and PAP). 3’
cleavage of SV40L is done in the same way except without any additional PAP. A. 3’ cleavage of Ad2L3
RNA carried out with 0.5 mM ATP (control), 0.5 mM of either 2’dATP, 3’dATP, AppCp, ApCpp, gamma-SATP, or GTP (ATP analogs). Bar graph shows 3’ cleavage averages (%) and their standard deviations
from three independent experiments. B. 3’ cleavage of Ad2L3 RNA carried out with 1 mM ATP (control), 1
mM of either AppCp or AppNHp (ATP analogs). White gaps between lanes indicate removal of irrelevant
gel lanes. Bar graph shows 3’ cleavage averages (%) and their standard deviations from four
independent experiments. C. Structure image for ATP analogs. X is located between β and γ phosphates.
In ATP, X represents oxygen, while in AppNp and AppCp, X represents either -NH- or -CH2-, respectively.
D. 3’ cleavage of SV40L carried out with 0.5 mM ATP (control), 0.5 mM of either 2’dATP, 3’dATP,
AppCp, ApCpp, gamma-S-ATP, or GTP (ATP analogs). Bar graph shows 3’ cleavage averages (%) and
their standard deviations from four independent experiments. Since only one of the experiment was done
with GTP, there is no standard deviation for this analog in 3’ cleavage with SV40L RNA.
Figure 7A shows that GTP does not stimulate any in vitro 3’ cleavage of Ad2L3 RNA precursor
and therefore, with this substrate, does not substitute for the cleavage stimulatory effect of ATP. The
same figure also shows that when γ-S-ATP is substituted for ATP in the presence of Ad2L3, the R.C. is

42

down to 48% as compared to 100% R.C. of ATP. Hence, γ-S-ATP stimulates 3’ cleavage of Ad2L3 to
about one half the level of ATP. Both, GTP and γ-S-ATP suggest that the structure of the analog
molecule is responsible for its stimulatory effect on 3’ cleavage activity. Comparison of R.C.s for ATP
(100%) and GTP (11%) shows that the structure of the nitrogenous base is important for the 3’ cleavage
activity. In the case of γ-S-ATP, where cleavage is stimulated but does not occur as well as it does with
ATP, the size difference between ATP and sulfur-containing analog indicates that both size and structure
of the compound may play a role in 3’ cleavage activation. Results for the 3’ cleavage of SV40L precursor
with GTP and γ-S-ATP analogs, were similar to those of Ad2L3 RNA, no significant effect and moderate
stimulation of 3’ cleavage, respectively (Fig 7D).
Earlier studies found that two ATP analogs, ApCpp and AppCp, promote 3’ cleavage activity with
the Ad2L3 substrate (100). ApCpp analog, which has a non-hydrolyzable α-β bond, promotes 3’ cleavage
activity and inhibits polyadenylation, while AppCp with β-γ non-hydrolyzable bond is thought to facilitate
cleavage and promoted synthesis of a short poly(A) tail (100). However, since the sequence of the Ad2L3
product after the reaction with AppCp analog was not obtained, it is possible that the Ad2L3 substrate
was polyadenylated without prior occurrence of the 3’ cleavage step. In the case of tk RNA precursor,
efficient cleavage occurred with ApCpp and minimal to none 3’ cleavage activity was observed with
AppCp (113). ApCpp analog seems to have stimulatory effect on cleavage, while the role of AppCp is
somewhat ambiguous.
In order to form a protein polyadenylation complex (50S) on the Ad2L3 precursor, presence of
either ATP, ApCpp, or AppCp is required in the 3’ processing protein mixture of the HeLa NxT (111).
Similarly, gel retardation analysis showed that ATP is required for protein polyadenylation complex to
form with tk precursor and that either dATP, ApCpp, or AppCp can replace ATP (113). In our experiments
with Ad2L3 substrate, we observe that ApCpp can induce a low level of cleavage, 22%, as compared to
that of 100% with ATP (Fig 7A), while there was no cleavage induced with AppCp analog (Fig 7A, lane 6).
These results were in line with the results from experiments of Zhang and Cole with the tk RNA precursor
and AppCp (113). When tested with SV40L substrate, ApCpp produced moderate levels (see H 2O) of
cleavage (40%), while AppCp seemed to inhibit cleavage to R.C. of 17% (Fig 7D). Unlike SV40L, Ad2L3
substrate requires ATP for cleavage; therefore, the results in Figure 7A show only that AppCp does not
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stimulate cleavage with Ad2L3 substrate and cannot provide any evidence for direct AppCp inhibition of 3’
cleavage with Ad2L3. So far, inhibition of 3’ cleavage of SV40L by AppCp indicates that the γ-phosphate
transfer may be required for enhanced 3’ cleavage activity of SV40L RNA. If that is the case then the
phosphate transfer may also be required for ATP to stimulate 3’ cleavage of Ad2L3 RNA. Hence the
definitive role of ATP in cleavage could be that of γ-phosphate contributor to either a compound or a
protein.
To confirm that the γ-phosphate transfer is required for the in vitro 3’ cleavage, another β-γ nonhydrolyzable bond analog, AppNp, was tested in the 3’ cleavage reaction. Unexpectedly, despite having
the β-γ non-hydrolyzable bond, like that of AppCp analog, AppNp showed stimulation of 3’ cleavage with
Ad2L3 substrate. Without any compound, the R.C. of Ad2L3 substrate is at 8%, while addition of AppNp
stimulates 3’ cleavage to the R.C. of about 36% (Fig 7B). While AppNp does not stimulate the 3’ cleavage
of Ad2L3 as well as ATP (100%), its stimulation effect is significant enough to show that an analog with
the β-γ non-hydrolyzable bond (or a phosphate that can be transferred by a protein kinase) is capable of
stimulating 3’ cleavage reaction with the Ad2L3 substrate. Although both analogs, AppCp and AppNp,
have γ-phosphates that cannot be hydrolyzed from these compounds or transferred to a protein via
phosphorylation; the two non-hydrolyzable analogs produce opposing results where AppCp appears to
inhibit and AppNp is able to stimulate 3’ cleavage activity. Since a non-hydrolyzable ATP analog is
capable of stimulating the 3’ cleavage, this result suggests indirectly that the in vitro function of ATP in 3’
cleavage is not that of a γ-phosphate donor but possibly that of a cofactor. It appears that the ATP
molecule is acting as a binding-cofactor, where it could be carrying out its effects on the 3’ cleavage
activity by binding to a target protein, as initially suggested by Sperry and Berget (112).
In conclusion, our experiments with ATP and its analogs show that to an extent the 3’ cleavage
activity of pre-mRNA substrates can be determined by the structures of these compounds. In some
cases, in the example of Ad2L3 substrate in a reaction with ATP or 2’ dATP as well as in the example of
SV40L with 2’ dATP, the effects of ATP and its analog are significant. The Ad2L3 substrate requires ATP
for 3’ cleavage and can be replaced with 3’ dATP, ApCpp, or ATPSγ, although the 3’ cleavage stimulation
would not be as significant as with ATP. The 2’ dATP is even more effective than ATP. The cellular
concentration of 2’dATP is thought to be lower than that of ATP (101, 110), which is reflective of ATP as a
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molecule that is involved in several cellular processes and 2’ dATP as mainly a component of DNA
replication. Since 3’ processing is a co-transcriptional event, the increased effectiveness of 2’ dATP as
compared to ATP could be explained by a hypothesizing that 2’ dATP is possibly mimicking the binding of
a 3’ processing protein to the ssDNA. The SV40L substrate is affected by ATP analogs in the same
manner as Ad2L3 substrate, except SV40L does not require ATP for its 3’ cleavage, although when
added, ATP enhances the 3’ cleavage of this substrate. By comparing the effects of ATP vs 2’ dATP or 3’
dATP, and those of ATP vs GTP on the 3’ cleavage activity, it can be concluded that the structures of the
nitrogenous base and ribose sugar are important to the outcome of the reaction.
Another significant result obtained from the experiments with ATP analogs is seen with the
AppCp compound. When used with Ad2L3 substrate, this compound does not stimulate any cleavage,
while when used with SV40L it actually inhibits 3’ cleavage reaction. This could indicate that AppCp is an
inhibitor of the 3’ cleavage. Since AppCp has a non-hydrolyzable β-γ bond, the cleavage results with
AppCp suggest that this bond has to be hydrolyzed in order for the 3’ cleavage to occur. The requirement
for the β-γ bond hydrolysis indicates that the role of ATP could be that of a kinase substrate for the
purpose of protein phosphorylation.
Finally, the results in Figure 7B show that a non-hydrolyzable analog AppNp can stimulate the 3’
cleavage of Ad2L3 substrate. This result demonstrates that a transferrable γ-phosphate in the context of
ATP is not required for its stimulatory effect on the 3’ cleavage reaction. Therefore the hypothesis that the
stimulatory effect of ATP on the 3’ cleavage occurs by having γ-phosphate of ATP transferred to a protein
via protein phosphorylation is not supported by our results.
2.3.2

γ-phosphate Transfer is not Required for 3’ Cleavage Activity
It is known that for its activity a kinase enzyme requires both ATP and the Mg 2+ ion (141). An

experiment was designed to test if ATP affects the in vitro 3’ cleavage activity of Ad2L3 RNA by acting as
a kinase substrate. To test this proposition we utilized the fact that when dephosphorylated NxT loses its
3’ cleavage activity. This dephosphorylation effect was previously traced to the CFm fraction and it was
shown that adding untreated CFm fraction back to a dephosphorylated NxT restores the 3’ cleavage
activity. Therefore if ATP is stimulating 3’ cleavage activity by acting as a kinase substrate then it could be
implementing its effect on the 3’ cleavage activity by phosphorylating a CFm fraction protein. Figure 8
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shows an experiment where NxT was dephosphorylated to make it 3’ cleavage inactive. CFm together
with either ATP, Mg2+, or both, was then added back to dephosphorylated NxT in a 15 minute precleavage reaction incubation period in order to provide favorable protein kinase reaction conditions. The
idea is that if ATP is functioning as a kinase substrate during normal in vitro cleavage, combining ATP
and Mg2+ should enhance this effect in comparison to ATP or Mg2+ alone. Because there is a general ATP
(or 2’-dATP) requirement, and in view of our previous CFm dephosphorylation results, we used a preincubation period at the start of the normal 2 h cleavage reaction period. The presumed Mg2+-dependent
kinase activity was then quenched by adding excess EDTA to chelate all Mg 2+ ions after which the 3’
cleavage reactions were allowed to proceed for another 105 min. Pre-incubations of dephosphorylated
NxT with ATP, Mg2+and either BSA, CPSF, or CstF fractions were also carried out as negative controls
since we know these factor fractions are not capable of rescuing the 3’ cleavage activity (13). The preincubation that contained dephosphorylated NxT, together with CFm, ATP, and Mg 2+ was carried out to
simulate the kinase active conditions (Fig 8, lane 5). Pre-incubations with either ATP or Mg2+ (Fig 8, lanes
6 and 7) were done as control comparisons to the pre-incubation with the kinase active conditions (lane
5).

Figure 8. The simulated kinase conditions do not enhance the
in vitro 3’ cleavage of Ad2L3 substrate. 5’ and 3’ RNA fragment
labels are on the left side of the gel. R.C. is 5’ fragment/ uncleaved
RNA in percent at the bottom of the gel. Input lane is RNA alone
(lane 1). Lane 2 contains HeLa NxT that was not treated with
phosphatase. NxT was dephosphorylated for reactions in lanes 39. Add-back indicates the components added back to a
dephosphorylated NxT to rescue 3’ cleavage activity. During addback indicates that either Mg2+ or ATP or both were added together
with the Add-back component for a 15 min pre-incubation. After
pre-incubation, all Mg2+ was chelated with EDTA and the 3’
cleavage reactions were allowed to proceed for another 105 min.

As shown in Figure 8, lane 5, pre-incubation of CFm with ATP and Mg2+ does not rescue 3’
cleavage activity of a dephosphorylated NxT above those of the control reactions (lanes 6 and 7). If the
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role of ATP in 3’ cleavage was that of kinase substrate then pre-incubation of CFm at optimal kinase
conditions should enhance the 3’ cleavage rescue above those of the control reactions (lane 2, 6, and 7).
However, the 3’ cleavage activity of this reaction is actually below the activities of the reactions with ATP
or Mg2+ only (lanes 6 and 7). This indicates that the optimal kinase conditions (ATP together with Mg2+)
may actually have a negative effect on the rescue of the 3’ cleavage activity. The results of this
experiment do not support the hypothesis that the ATP function in the 3’ cleavage reaction is that of a
kinase substrate. In other words, the ATP function in the 3’ cleavage of the Ad2L3 substrate does not
appear to be through the transfer of its γ-phosphate for the purpose of protein phosphorylation of the
CFm fraction.
The observations from 3’ cleavage experiments with ATP analogs suggests that maybe the entire
structure of ATP molecule, without hydrolysis of its phosphate bonds, has a direct effect on the
3’cleavage reaction. This idea was first expressed by Sperry and Berget in 1986 (112). This possibility is
consistent with previous findings where cleavage proceeds normally in presence of high EDTA
concentration (8 mM), a condition under which most kinases are inhibited from hydrolyzing
phosphodiester bonds of the ATP molecules (14). As already stated above, the non-hydrolyzable ATP
analog, AppNp, was used in the 3’ cleavage reaction with Ad2L3 RNA, to assay the possibility that either
the γ-phosphate transfer from ATP to another molecule or its phosphodiester bond hydrolysis may be
required for ATP to have its effect on cleavage (Fig 7B). Figure 7B shows that with Ad2L3 substrate,
AppNp stimulates cleavage above background levels to the R.C. of 36%. Although AppNp does not
stimulate cleavage as strongly as ATP, the ability of this non-hydrolyzable analog to produce cleavage
suggests that γ-phosphate hydrolysis and/or transfer is not required for the ATP molecule to have its
stimulatory effect on the 3’ cleavage activity and cofactor activation is a more likely possibility. This same
conclusion, from the experiment with AppNp analog, is supported by experiment in Figure 8 where the
optimal kinase conditions neither enhance the 3’ cleavage reaction nor produce any significant amount of
the 3’ cleavage activity. The above results strongly suggest that the intact ATP molecule confers its
stimulatory effect on cleavage by acting as a cofactor to one of the proteins within the 3’ processing
complex.
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2.3.3

AppCp is a General Inhibitor of 3’ Cleavage Activity
The in vitro cleavage experiments with AppNp and the experiment with the simulated kinase

conditions are consistent with the idea that ATP does not have to be hydrolyzed to have its effect on
cleavage. These results indicate that ATP most likely acts as a cofactor to a protein within the 3’ cleavage
reaction. Also, AppCp appears to have inhibitory effect on SV40L RNA. To definitively show that AppCp
inhibits 3’ cleavage, the 3’ cleavage reactions of the ATP-requiring Ad2L3 substrate were carried out with
combination of 1 mM ATP and either 0.1, 0.3, 0.5, 1.0, or 2.0 mM AppCp. The result shows that the 3’
cleavage activity is dose-dependently inhibited by increasing concentrations of AppCp while ATP is kept
constant at 1 mM (Fig 9).
From research by another group, it is known that the optimal in vitro 3’ cleavage activity with
Ad2L3 substrate occurs at 1 mM ATP and begins to be inhibited somewhere between 1 mM and 5 mM
ATP (100). It is possible that the 3’ cleavage inhibition is not caused by AppCp but by the combined
concentration of the two analogs, ATP and AppCp. That is the sum of the ATP and AppCp concentrations
produces the same inhibitory effect on the 3’ cleavage as that of high ATP concentration. However, in
Figure 9, lane 5, the 1.1 mM sum of ATP and AppCp is very close to the 3’ cleavage optimal 1 mM ATP
concentration and therefore unlikely to cause a 28% decrease in R.C., it is more probable that this
inhibition is specific to the AppCp molecule. Similarly in lane 6, the concentrations of ATP and AppCp add
up to 1.3 mM, which is unlikely to be high enough to cause a 50% decrease in 3’ cleavage activity. It
appears that 1.1 mM and 1.3 mM concentration sums of these compounds are not responsible for the 3’
cleavage inhibition but that the AppCp analog itself is causing this inhibition. Hence there appears to be a
true 3’ cleavage inhibitory effect by the AppCp compound.
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Figure 9. AppCp inhibits ATP-activated 3’ cleavage of Ad2L3 substrate. 5’ and 3’ RNA fragment
labels are on the left side of the gel. R.C. (5’ fragment/ uncleaved RNA) in percent is at the bottom of the
gel. Input lane is RNA alone. H2O lane is cleavage reaction without ATP or its analog. In vitro 3’ cleavage
of Ad2L3 RNA substrate is carried out in a reconstituted protein mix (CPSF, CstF, CFm and PAP).
Specified concentration or plus and minus signs indicate presence and absence of the corresponding
compound. Bar graph shows 3’ cleavage averages (%) and their standard deviations from three
independent experiments.
2.3.4

ATP as Protein Cofactor for ATP-Binding Proteins of CFm
Moore, Skolnik, & Sharp (21) data, which used HeLa NxT as a source of the cleavage factors,

showed that ATP is necessary for 3’ pre-mRNA cleavage of the Ad2L3 substrate, while the experiments
above, which used the DEAE factors, showed that ATP is required for cleavage of Ad2L3 RNA and
enhances cleavage of SV40L RNA. The experimental results from the previous two sections suggest that
ATP does not function as either an energy donor or a kinase substrate but as a possible protein-binding
cofactor of the in vitro 3’ cleavage reaction. Therefore the focus will now be shifted to the role of ATP as a
possible protein-binding cofactor. Since the 3’ cleavage complex contains nucleotide binding proteins,
such as PAP, CFIm25, and Clp1, it is reasonable to suspect that ATP could exert its effect on 3’ cleavage
activity by binding to one of these proteins through one of their ATP-binding sites. The experiments
described next explore this possibility.
First, PAP was tested as the ATP-binding target in the 3’ cleavage reaction with Ad2L3 RNA.
Previous studies show that using FPLC, HeLa NxT can be separated into the 3’ cleavage activity fraction
and the PAP (polyadenylation activity) fraction (20). To separate the two activities, the HeLa NxT was
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precipitated with (NH4)2SO4 to concentrate nuclear proteins. The concentrate was then resuspended in
Buffer D and separated into the 3’ cleavage specificity factor (CSF) and PAP fraction via Superose 6 (size
exclusion) column. When tested individually with the SV40L RNA, the CSF retained the specific 3’
cleavage activity of the HeLa NxT, while PAP was active but lost its specificity (20). This group also
shows that while SV40L can be 3’ cleaved by CSF alone, the Ad2L3 RNA is cleaved only when both CSF
and PAP are present in the reaction (20). The requirement of both CSF and PAP for the 3’ cleavage
activity of Ad2L3 RNA substrate is thought to representative of most other RNA substrates. Incidentally,
this same group stated that the recombining of CSF and PAP fractions restores the specificity of the
polyadenylation reaction.
Since mixing the two fractions reconstitutes the 3’ cleavage activity of Ad2L3 pre-mRNA,
recombinant versions of PAP, with for example site-specific mutations, can be used in place of the
Superose 6 column PAP fraction to reconstitute the 3’ cleavage and to examine if reduced ATP/PAP
binding in the mutPAP proteins has an effect on the 3’ cleavage activity. To test the possibility of ATP as
the cleavage stimulatory cofactor that functions via PAP, the 3’ cleavage reactions were set up to contain
CSF, Ad2L3, and either wtPAP or one of three mutPAPs. Some of the mutPAPs were previously shown
(in the context of C-terminally truncated version of PAP that contained the entire polymerase domain but
lacked the C-terminal domain) to have low binding affinity for ATP. The Doublie group demonstrated that
residues, K228 and Y237, involved in ATP binding, when mutated show large increase in K M values or
low capacity for ATP binding, while the Kcat was not significantly affected (89). The bovine wtPAP protein
has the KM value of 0.229 mM, while K228A and Y237A, have KM value of 2.191 and 1.402, respectively.
These residues contact the phosphate tail or more specifically γ-phosphate of ATP (Fig 10B) (89).
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Figure 10. Graphical representation of PAP
steady state kinetics results. A. PAP domain
diagram. B. The mutated residues with
increased KM for RNA and ATP are shown in
red and cyan, respectively. Residues in beige
have wild-type KM. ATP is shown in blue. The
RNA binding motif is in yellow. Mg2+ ion is
shown as a green sphere. Green dotted lines
represent hydrogen bonds.
Adapter from Martin et al., 2004 (89).

The PAP mutants with the largest increase in KM values were assayed for possible effect on the
3’ cleavage activity due to their decreased ATP-PAP binding. Three new mutant plasmids were made
from pUK-wt His-PAP plasmid, which encodes the full length bovine PAPII protein (142) one for each of
the following mutations: K228A, Y237A, and the novel double mutant K228A/Y237A (Fig 11).
Figure 11 graphically summarizes the PAP mutations that were made for this experiment. Figure
11A and B shows the protein and mRNA sequences of wtPAP with amino acids and codons for K228 and
Y237 highlighted in red. Figure 11C presents sequenced region of the plasmids that were made to
contain K228A, Y237A, and K228A/Y237A mutants.
As a gauge of ATP-binding, we used the non-specific PAP polyadenylation reaction. Manganese
relaxes the sequence specificity of polyadenylation (no longer requires AAUAAA sequence) but uses ATP
to add a poly(A) tail to any RNA substrate. Figure 12A demonstrates that at 1 mM ATP and 1 mM MnCl 2,
the nonspecific polyadenylation of Ad2L3 RNA with K228A and Y237A mutPAPs (lanes 3 and 4) is nearly
as effective as that of wtPAP (lane 2). However, the K228A/Y237A double mutPAP is not active (lane 5).
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Figure 11. Protein and mRNA sequences of wtPAP taken from PubMed database, and Macrogen
sequencing of mutPAP plasmids. A. Wild-type protein sequence of bovine alpha Poly(A) Polymerase.
Amino acids (K228 and Y237) that were eventually mutated to alanines are indicated in red. B. Wild-type
mRNA sequence of bovine alpha Poly(A) Polymerase, codons highlighted in red indicate K228 and Y237.
C. Macrogen services were used to sequence mutant plasmid that were generated via PCR Mutagenesis
Kit (Agilent Technologies). Underlined codons indicate lysine or tyrosine to alanine mutations (K228A and
Y237A).
If ATP acts through PAP then the 3’ cleavage reaction containing CSF, Ad2L3 RNA, and the
K228A/Y237A double mutPAP should show either partial or complete loss of 3’ cleavage activity.
Figure 12 shows that reconstituting 3’ cleavage reaction with low ATP-binding mutPAPs (K228A,
Y237A, and K228A/Y237A) produces no change in amount of 3’ cleavage product as compared to that
produced with wtPAP. The mutPAPs show no reduction in R.C.; reduction in R.C. would be expected if
ATP were carrying out its stimulatory effect on the 3’ cleavage through binding to PAP. However, the 50
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ng PAP (49 nM) is in large excess over the <5 nM RNA as well as the other cleavage factors supplied by
the HeLa cell Superose 6 CSF fraction. For this reason, the cleavage experiment was repeated with
about 10 ng PAP and the ATP concentration equal to the Km of the wtPAP, 0.23 mM. That experiment
(not shown here) produced the same results as the experiment in Figure 12. Since the polyadenylation
inactive dmPAP generated 3’ cleavage activity equal to that of the wtPAP, the conclusion was that ATP
does not produce its effect on the 3’ cleavage activity through PAP.

Figure 12. Nonspecific polyadenylation and 3’ cleavage reactions of Ad2L3 RNA in presence of wt
or mutPAP show that ATP does not stimulate 3’ cleavage activity through the PAP protein. R.C. (5’
fragment/ uncleaved RNA) is in percent and at the bottom of the gel. Input lane is RNA alone. A.
Nonspecific polyadenylation takes place in presence of 1 mM ATP, 1 mM MnCl2, and 50 ng of either wt or
mutPAP. Wt (2x) is 100 ng of wtPAP. B. No PAP lane contained Buffer D instead of any PAP protein. All
lanes except for Input contain 50 ng of CSF and 1 mM ATP. His-tag labeled wt and mutPAPs (K228A,
Y237A, and K228A/Y237A) were recombinant bovine proteins, produced in E.coli. HeLa PAP was
prepared via Superose 6 column (20).

Although ATP does not appear to act through the dmPAP, another possibility exists where the
two mutations within the dmPAP alter the protein structure in such a way that it becomes activated, i.e.
adopting a structure that eliminates the ATP requirement for the 3’ cleavage activity. To explore this
possibility an experiment was developed where the dmPAP alone, without ATP, was added to the 3’
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cleavage reaction. It was hypothesized that if this mutant protein generated 3’ cleavage activity on its own
without any ATP, then this would be a constitutively active mutant protein that does away with the ATP
requirement, even though ATP does not act though PAP. In Figure 13, lanes 2 and 3 are controls, while
lanes 4 and 5 demonstrate that wtPAP requires ATP in order to produce above-background 3’ cleavage
activity. Lane 6 shows that without ATP, the dmPAP does not generate above-background cleavage
activity and therefore is not a constitutively active protein, in other words double mutant does not
eliminate the ATP requirement for the 3’ cleavage activity of the Ad2L3 substrate. In conclusion, we
excluded PAP from being a possible target of ATP-binding during the 3’ cleavage reaction or the dmPAP
as a constitutively active protein for the 3’ cleavage activity.

Figure 13. dmPAP is not a constitutively active protein of
the 3’ cleavage activity. R.C. (5’ fragment/ uncleaved RNA)
is in percent and at the bottom of the gel. Input lane is RNA
alone. All lanes contain CSF. Buffer lane contains Buffer D in
place of any PAP protein. Plus/minus sign indicates presence
or absence of 0.23 mM ATP. Where indicated 5 ng of either wt
or dmPAP were added per reaction. Wt(2x) stands for
doubling of the wtPAP amount, i.e. 10 ng of wtPAP in lane 8.

The next protein that was tested for its possible role in the 3’ cleavage activity via ATP was the
CFIm25. Structural and biochemical evidence suggest that the NUDIX domain of CFIm25 protein binds to
mono and diadenosine nucleotides but does not hydrolyze them (Fig 14A and B) (65). Binding of CFIm25
Nudix domain to the UGUA cis element of pre-mRNA also occurs in the Nudix domain region of CFIm25,
and binding to RNA and Ap4A (and ATP too) should be mutually exclusive. For this reason, it is unlikely
that ATP activates pre-mRNA cleavage through this protein; rather, the long-known (100) ATP-dependent
inhibition of cleavage is a possibility since at high ATP concentrations a scenario in which ATP displaces
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the RNA substrate from the CFIm25 Nudix site, preventing cleavage, is possible. In a negative way then,
it is possible that small molecules like ATP and its analogs may regulate the binding of the CFIm25 to
pre-mRNA and influence 3’ cleavage reaction (66).
The effect of CFIm25 to ATP analog (Ap4A) binding on the 3’ cleavage activity was assayed
using the Ad2L3 RNA substrate (Fig 15). Since Ad2L3 pre-mRNA substrate requires ATP for its
3’cleavage, ATP was first replaced with Ap4A to see if this analog, whose binding to CFIm25 has been
experimentally observed but only in the context of purified recombinant protein, can substitute for ATP
during the 3’ cleavage reaction. Note that in the context of the purified CFIm25 protein, the Ap4A binds

Figure 14. Crystal structure of CFIm25 homodimer bound to two molecules of Ap4A via Nudix
domains. Arrow indicates location of the Ap4A molecule. A. CFIm25 protein crystal structure. B.
Chemical structure of the Ap4A molecule. Adapted from Coseno et al., 2008.

with a somewhat high affinity, with an equilibrium dissociation constant, Kd= 2.44 ± 0.49 µM (65). As
shown in Figure 15A, the increasing amounts of Ap4A, from 1 µM to 1 mM, were used in place of ATP,
and as expected, none of these reactions produced stimulation of the 3’ cleavage activity. Hence, in the
absence of ATP, Ap4A does not appear to have any effect on the 3’ cleavage reaction of PAP- and ATPdependent Ad2L3 substrate. Next, Ap4A was tested as an antagonist to ATP. The Kd value between ATP
and CFIm25 is 1.53 ± 0.18 mM (65). For these 3’ cleavage reactions, the ATP concentration was kept
constant at 0.5 mM, while increasing the Ap4A concentration from zero to 0.5 mM (Fig 15B). None of the
Ap4A concentrations were able to inhibit the stimulatory effect of ATP on the 3’ cleavage reaction. Thus in
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the context of the native cleavage factors (DEAE factors, including wt PAP) Ap4A appears not to displace
RNA and thereby fails to inhibit the ATP-dependent cleavage. It is known that the UGUA sequence that is
common in pA signals and is present in Ad2L3 and SV40L binds CFIm25 more tightly when bound to the
CFIm68 subunit (64). Though our result may mean that high ATP concentrations are not responsible for
the long-known ATP-inhibition of Ad2L3 cleavage through CFIm25 Nudix domain binding, it is possible
that the RNA outcompetes any small molecule Nudix ligand like Ap4A or ATP under normal cleavage
reaction circumstances. In summary, if ATP has an effect on cleavage through CFIm25, based on recent
structural biology in the area, it is likely to be a negative regulatory role. We were not able to shed light on
this in our experiment.

Figure 15. Ap4A in neither activator nor
inhibitor of Ad2L3 pre-mRNA 3’ cleavage
activity. 5’ and 3’ RNA fragment labels are
on the left side of the gel. R.C. (5’
fragment/uncleaved RNA) in percent is at
the bottom of the gel. Input lane is RNA
alone. H2O lane is cleavage reaction
without ATP or its analog. A. Ap4A as
cleavage activator. B. Ap4A as cleavage
inhibitor. Lanes 5-8 contain the following
concentrations of Ap4A: 0.5, 2.5, 12.5, and
500 µM.

Clp1 is another 3’ processing protein with the ATP-binding site. In mammals Clp1 is required for
3’ cleavage, while it is dispensable for poly(A) addition (76). Mammalian Clp1 has the RNA kinase activity
and activates small interfering RNAs (siRNA) for incorporation into silencing complex (85). To date no
ATPase activity was identified as a necessary function for the 3’ processing. In yeast Clp1 has been
shown to bind to Pcf11 (143). A number of groups investigated the role of ATP to Clp1 binding in 3’
cleavage function via Clp1 to Pcf11 binding in yeast (Fig 16) (81-84, 144).
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Figure 16. Crystal structure of yClp1 bound to ATP and a Pcf11 fragment. Adopted from Xiang et al.,
2014.

Together these yeast studies suggest that normally ATP binds to but is not hydrolyzed by yeast
Clp1 (yClp1). They also suggest that yClp1 structural conformation or more specifically its ATP-binding
site conformation regulates Clp1-Pcf11 interaction which in turn determines the 3’ cleavage activity (82).
The ATP binding to Clp1 may be dispensable for the 3’ cleavage in yeast, however, yeast and
mammalian Clp1 proteins have only 24% homology, meaning that conformations of the two homologs
may differ and so may the effects of ATP binding to Clp1 on the 3’ cleavage activity (84). Since, from the
yeast studies listed above, it is now known that ATP-binding site of Clp1 may regulate Clp1-Pcf11
interaction, which in turn regulates 3’ cleavage efficiency, an experiment was designed to see if AppCp
inhibition of 3’ cleavage occurs through disruption of the contact between Clp1 and Pcf11 proteins. This
possibility was tested through the use of co-IP of Pcf11 together with Clp1 in presence of either ATP or
AppCp or no added nucleotide (Fig 17).
Pcf11 protein co-IPs together with the Clp1-Flag protein Figure 18, lane 9. The goal was to add
AppCp to the IP, while simulating conditions similar to those of the 3’ cleavage reaction; to see if AppCp
can prevent Pcf11 from co-IPing with Clp1 (Fig 17). To ensure as little ATP as possible, the standard
hexokinase ATP-depleting procedure was used.
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Figure 17. Schematic of four Clp1-Flag co-IPs from either untransfected or Clp1-Flag stably
expressing HeLa lysate. Highlighted in green and purple are the experimental steps and expected
results. Step 1 is depletion of ATP in all four flasks. In Step 2, Flag Affinity Beads are added to all flasks
(IPs). Flasks 1, 2, and 3 represent different types of controls, of which only flask 3 has ~3 nM Ad2L3, 50
nM CP, and 4 mM ATP added to it. Flask 4 is the same as flask 3 except AppCp was added instead of
ATP.
To test this hypothesis, two types of lysates were made, one type was from untransfected HeLa
cells (control) and another type of lysate was from HeLa cell stably expressing Clp1-Flag protein. These
lysates were used to performed four co-IPs, all of which were at first treated with 2 mM glucose and 0.6 u
of hexokinase to deplete them of ATP (14). After ATP depletion, two control co-IPs, one with HeLa lysate
and another with Clp1-Flag lysate, were incubated with Flag Affinity Beads only. The other two of the four
IPs were both done with Clp1-Flag lysates and besides Flag Affinity Beads, to simulate in vitro 3’
cleavage conditions, both contained ~3 nM Ad2L3 RNA substrate and 50 mM CP, and either 4 mM ATP
or 4 mM AppCp. These high concentrations were used to leave no doubt of ATP (and AppCp) saturation
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of any possible binding site within the cleavage factors. It was predicted that in the ATP depleted lysate
and under 3’ cleavage simulated conditions, AppCp would bind to and change structural conformation of
the Clp1 protein, which as a result of this would lose its ability to bind Pcf11. Therefore, Pcf11 protein
would not be able to co-IP with Clp1-Flag protein. This would test that ATP and its analogs could possibly
act on the 3’ cleavage activity through binding to the Clp1 protein. However, the results of this experiment
did not show any disruption in Clp1-Pcf11 interaction as consequence of AppCp addition to the ATP
depleted lysate (Fig 18).

Figure 18. Clp1-Pcf11 co-IPs show that neither ATP-depleted lysate nor AppCp-containing/ATPdepleted lysate lose Clp1-Pcf11 interaction. 20 µg of each sample were loaded per lane, except
elutions were loaded in their entirety. M stands for protein marker. Control and Clp1-Flag Lysate
represent lysates from HeLa cells and HeLa cell stably expressing Clp1-Flag protein, respectively. IP
Supernatants stand for unbound fraction removed from beads at the end of the IP. IP lysates of all four
samples were pretreated with glucose and hexokinase to deplete them of ATP. Control and Clp1-Flag IPs
served as controls, while only Clp1-Flag/ATP and Clp1-Flag/AppCp were incubated with 50 mM CP, 40 u
RNase Inhibitor, and 3 nM Ad2L3 RNA. Upper panel and lower panel were western blotted with Pcf11
antibody and Clp1 antibody, respectively. Arrows on the lower panel indicate stably expressed Clp1-Flag
and endogenous Clp1 proteins.

The experiment also showed that an excess of unbound ATP was not necessary to maintain
Clp1-Pcf11 association. Therefore such result suggests that ATP is unlikely to stimulate 3’ cleavage
reaction via binding to the Clp1 protein. One caveat however is that Clp1 may bind ATP with such high
affinity, due in part to a very slow rate of dissociation, such that during this experiment no ATP dissociates
from Clp1 and hence cannot be outcompeted by AppCp. While this may be true, we know that AppCp
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inhibits in vitro cleavage at this high concentration; and we can conclude with confidence that AppCp
does not inhibit cleavage by disrupting the Clp1-Pcf11 association. The experiment described above may
have to be repeated where whole cell lysates are dialyzed before they are ATP depleted and used for coIPs. The dialysis step would help to guarantee that most ATP is depleted from the cell lysates.
2.4

Conclusion
Some of the ATP analogs tested here were tested before by others, however, their intent was to

use these analogs as tools for establishing the in vitro 3’ processing conditions (14, 21, 100, 111-114).
Aside from 3’ cleavage reactions with recombinant PAP, for which Superose 6 column fractions were
used, the 3’ cleavage reactions in this chapter were done using the DEAE-fractionated factors. Using
much more highly purified CPSF, CstF, CFIm and CFIIm fractions in their 3’ cleavage reactions, Hirose
and Manley (14) showed that the 3’ cleavage of SV40L RNA is inhibited by 1 mM (and higher) ATP,
whereas here Figure 7D shows that 0.5 mM ATP stimulates 3’ cleavage activity of SV40L RNA. This
variation in result may be due to differences in purification methods of CPSF, CstF and CFm fractions.
Hirose and Manley used several different FPLC columns to purify their factor fractions, whereas here the
same factor fractions were purified using only the DEAE-sepharose column.
Combined together our results suggest that ATP stimulates 3’ cleavage of pre-mRNA precursors
and is essential for cleavage of Ad2L3 RNA substrate. The structure of ATP is important, variation in
structures of deoxyribose (2’dATP vs 3’dATP) and of nitrogenous base (ATP vs GTP), and the size of
either the phosphate tail or the whole molecule (ATP vs γ-S-ATP), and electron density and bond
orientation between β- and γ- phosphates (ATP, ApCpp, and AppNp vs AppCp), all determine the amount
of cleavage product formed.
Hence, the results of this chapter show that the structure of the ATP analog can determine the
level of the 3’ cleavage activity for the Ad2L3 substrate, and to a lesser extent the SV40L substrate, in
vitro. Also, the 3’ cleavage activity is induced by AppNp compound despite it having the β-γ nonhydrolyzable bond. Additionally, the 3’ cleavage activity is not enhanced by the kinase simulated
conditions. Both the experiment with AppNp and the one with the simulated kinase conditions argue
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against the requirement for γ-phosphate transfer from ATP during the 3’ cleavage reaction. Since ATP
analog structures can determine the result of the cleavage reaction, and do not require the transfer of
their γ-phosphates during 3’ cleavage, it is reasonable to assume that ATP may exert its function by
binding to a still unidentified cleavage factor protein. The conclusion then is that ATP is neither
hydrolyzed nor utilized as a kinase substrate but most likely binds to a protein and affects its structure
and activity.
It was also discovered that AppCp can inhibit cleavage reaction on its own or by competing with
ATP. Besides AppNp, AppCp is another β-γ non-hydrolizable analog which acts on the 3’ cleavage but
has the opposing effect to that of AppNp under the conditions tested here. The fact that AppCp may be
competing with ATP indicates that the two molecules are possibly acting on the 3’ cleavage through the
same protein-binding site. Although it could also be that these molecules have separate protein-binding
sites. The result from this experiment show that AppCp can counter ATP effect, and serves as additional
evidence for the hypothesis that ATP and its analogs act as protein-binding cofactors.
Three ATP-binding proteins, CFIm25, PAP, and Clp1, were tested for their role in activating 3’
cleavage activity via ATP. First, ATP-binding site of PAP was mutated in the way that reduced this
protein’s ability to bind ATP. The idea was that if ATP acts on the 3’ cleavage through PAP, then with the
mutPAPs there should be either reduced or zero 3’ cleavage activity. However, even the mutPAPs, with
low ATP binding capacity, produced same amount of the 3’ cleavage as the wtPAP. As a result, PAP was
excluded as the target for ATP cofactor binding. Next since the CFmI25 binding to Ap4A nucleotide and
its binding to UGUAN cis element of RNA substrate are mutually exclusive, Ap4A was tested for its
possible role as either activator or inhibitor of the 3’ cleavage activity. However, neither of the effects were
present in the 3’ cleavage reactions. Lastly, a co-IP experiment was set up to examine if Clp1-Pcf11
interaction can be determined by either ATP or AppCp via the ATP-binding site of Clp1. From
experiments with yeast, it is known that the ATP-binding site of Clp1 modulates Clp1 to Pcf11 binding,
which when disrupted, will abolish 3’ cleavage activity (82). To interfere with Clp1-Pcf11 interaction and to
examine if ATP and its analogs act through the ATP-binding site of Clp1, the Clp1-Flag containing HeLa
cell lysates were first depleted of their ATP, and then subjected to Flag IPs under the in vitro 3’ cleavage
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conditions; that is with CP, Ad2L3 RNA substrate, and either ATP or AppCp. It was hypothesized that in
presence of ATP, Pcf11 would co-IP together with Clp1, while if AppCp were used, it would interfere with
this co-IP interaction. However, no disruption in Clp1-Pcf11 interaction was observed in presence of
AppCp compound, the two proteins co-IPed together as well as they did in presence of ATP. Therefore, it
appears that Clp1 is not the protein through which ATP imparts its effect on the 3’ cleavage activity.
Although 3’ processing machinery and its specific activity (CFIImA), IP and co-purify, respectively
(76, 145), with proteins from other processes, such as transcription and splicing, which may include more
of ATP-containing proteins; it is unlikely that proteins other than those of 3’ processing complex are
responsible for influencing 3’ cleavage of Ad2L3 RNA via ATP. Because ATP’s effect on cleavage is
determined by RNA substrate (SV40L vs Ad2L3), it follows that ATP is affecting those proteins which are
binding to or in close association to the cis elements of the 3’ cleavage site.
From the experiments in this section, the conclusion is that ATP does not act on the 3’ cleavage
activity through either PAP, CFIm25, or Clp1 proteins. Instead the more likely speculation would be that
ATP binds to some other 3’ processing protein and acts through it to impart its effect on the 3’ cleavage
activity. The binding between ATP and its target protein most likely occurs through ion-ion interactions
between ATP and a positively charged domain of that protein. Two possible candidates for this kind of
interaction with ATP are CPSF30, which binds to AAUAAA cis element through its zinc finger domains,
and Fip1 protein, which has R-rich C-terminal domain that binds U-rich cis elements (11, 31). These are
the two proteins with highly charged domain, both of which have a preference for binding to U-rich cis
elements (11). Since the nucleotide sequences and ATP requirement for cleavage of the two substrates Ad2L3 and SV40L - differ, it may be that ATP serve as a physical bridge between the Ad2L3 substrate
and the highly charges domain of either CPSF30 or Fip1. This bridging interaction would bring on
conformational changes of some of the 3’ processing proteins, resulting in their tighter binding to the
Ad2L3 substrate and therefore in induction of the 3’ cleavage activity.

This interaction can be

endogenous to some protein domains or it may be artificially induced by the excess of ATP in vitro.
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CHAPTER THREE: Role of Protein Phosphorylation in 3’ Cleavage Reaction

3.1

Introduction

3.1.1

Evidence for 3’ Cleavage Control by Phosphorylation of the Cleavage Factor Proteins
Several proteomic and some in vitro studies identified numerous PTM of the 3’ cleavage factors;

however, functions of these PTMs are not known (116). Proteomic studies conducted to identify
phosphorylation, lysine acetylation, arginine methylation, and lysine sumoylation of 3’ cleavage factors
show that phosphorylation is the most common PTM found among them (116). In vitro studies in our lab,
found that 3’ cleavage assay is strongly inhibited by dephosphorylated HeLa NxT (13). Figure 3 shows
that susceptibility to phosphatase was traced to CFm factor of the 3’ cleavage complex. The CFm factor
was able to restore 3’ cleavage activity of dephosphorylated HeLa NxT. The likely hypothesis to explain
the strong effect of phosphorylation on the 3’ cleavage activity would be that phosphorylation of CFm
fraction either initiates the binding of other protein factors to the 3’ processing complex or it enhances the
overall stability of this protein complex.
The hypothesis is that phosphorylation enables assembly of the active cleavasome – or precleavage complex of the factors - in vitro. The goal here is to identify the target protein(s) of
phosphorylation, whose unphosphorylated form suppresses - or at least does not allow, perhaps by
preventing required protein-protein complex formation – the 3’ cleavage activity.

3.2

Experimental Procedures

3.2.1

pIRESneo3-CFIm68-3XFlag, pIRESneo3-CFIm25-3XFlag, pIRESneo3-CFIm59-3XFlag Plasmid

Construction
These plasmids were made in the same manner as pIRESneo3-Clp1-3XFlag (described in
Section 2.2.5). The cDNA sequences of CFIm59 and CFIm68 were obtained from pcDNA3.1-CFIm59Myc-His6 and pcDNA3.1-CFIm68-Myc-His6, which were formerly made in our lab by Xiaozhou Pan.

63

Figure 19. Construction of pIRESneo3-CFIm25-3XFlag Plasmid. Enzyme restriction sites are in blue.
Forward and reverse primers have partial cDNA sequences of the CFIm25 protein and appropriate
restriction sites. Forward primer contains Kozak sequence.

A different strategy had to be used to sub-clone CFIm25 cDNA (Fig 19). This had to be done to
avoid sub-cloning the 6xHis and HA tags from pcDNA3.1-His6-HA-CFIm25 plasmid into the pIRESneo33XFlag plasmid. Two avoid the two tags, cDNA for CFIm25 was PCR amplified from pcDNA3.1-His6-HACFIm25 plasmid. The primers were specifically designed to include the Kozak sequence on the forward
primer. The 5’ end of each primer started with a specific restriction enzyme site to make it easier to subclone CFIm25 cDNA into the MCS of pIRESneo3-3XFlag plasmid, which already contains both the Flagtag followed by the stop codon. At the 5’ end the forward primer contained NheI restriction site followed
by the Kozak sequence and a short CFIm25 cDNA sequence (22 nucleotides): 5’-NheI- Kozak-22 nt of
CFIm25-3’. At the 5’ end, the reverse primer contained BstBI restriction enzyme site followed by a short
part of the protein C-terminal cDNA (22 nucleotides): 5’ BstBI-22 nt of CFIm25-3’. The NheI and BstBI
restriction sites, once incorporated into the PCR amplified cDNA of the CFIm25 protein, were then used
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to sub-clone the CFIm25 cDNA into the pIRESneo3-3XFlag plasmid. For the resulting plasmid, the entire
cDNA of pIRESneo3-CFIm25-3XFlag was sequenced to confirm accuracy of PCR and cloning steps.
3.2.2

Immunoprecipitations of CFIm68-Flag, CFIm59-Flag, CFIm25-Flag, or Clp1-Flag Protein for Use

in Add-Back (i.e. phosphoprotein rescue) Reactions
Four to six 15 cm plates of HeLa cells stably expressing one of the Flag-tagged proteins were
detached with 0.05% trypsin (Corning) for 5 min, washed in 1 ml of PBS, pelleted, snap frozen and
thawed to break the cell membrane. The cells were further lysed by gentle mixing in 125 µl of Buffer
D20Glyc (per 15 cm plate of cell pellet) for 10 min. The cells were centrifuged for 10 min at 10,000 rpm and
the lysates total protein concentrations were measured as in Section 2.2.1. Lysates were diluted with
equal volume of Buffer D20Glyc and incubated with 40 µl of Flag Affinity Beads (Sigma) for 2 h at 4C.
Beads were then washed three times with 200 µl of Buffer D20Glyc and eluted with 47 µl of Buffer D20Glyc
plus 3 µl of 5 µg/µl (1.75 mM) Flag peptide (Sigma) on a shaker for 30 min at 4C. IPed proteins were
quantified by western blotting with the corresponding antibody and used in Add-Back reactions. Note that
the Flag peptide, whose sequence is N-MDYKDHDGDYKDHDIDYKDDDDK-C, when included at 2 l per
12.5 l cleavage reaction, will be present during cleavage at  280 M. We make the assumption that this
peptide does not affect in vitro cleavage.
3.2.3

Immunoprecipitation of Pcf11 Protein for Use in Add-Back Reactions
20 µl of Protein AG beads (Santacruz) together with 90 µl of Pcf11 antibody (Santacruz) were

incubated on a shaker for 1.5 h. Beads were then washed three times with 600 µl of Buffer D 20Glyc and
incubated with 56 µl of DEAE-fractionated CFm for 3 h. The supernatant was removed, and the beads
were then again washed three times with 600 µl of Buffer D 20Glyc. Beads were not eluted but instead were
diluted with 1x volume of Buffer D20Glyc. This Pcf11/AG beads mixture was quantified by western blotting
with Pcf11 antibody (Proteintech) as well as with Clp1 antibody (Abcam) and used in add-back reactions.
In one experiment, 0.1% SDS was used for washing away any proteins that might have co-IPed
with Pcf11. This experiment was based on the previously published procedure (146). The idea was to
wash away co-precipitating proteins while preserving the antibody-antigen association. For this
experiment, Pcf11 IP was done as described above except 10 µl of AG beads, 22.5 µl of Pcf11 antibody
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(Santacruz), 15 µl of CFm, and 15 µl of Buffer D20Glyc were used for this IP. IP1 was not treated with SDS
(control). IP2 was washed three times with 200 µl of 0.1% SDS-containing Buffer D20Glyc. For IP3, 0.1%
SDS was included during the IP incubation step.
3.2.4

Add -Back of IPed CFIm68-Flag, CFIm59-Flag, CFIm25-Flag, or Clp1-Flag protein or Pcf11/AG

Bead Mixture to Dephosphorylated NxT
3 µl of NxT were dephosphorylated with 3 u of CIP at 1.5 mM concentration of MgCl 2 for 30 min
at 30C. To quench CIP, EDTA was added to NxT to a final concentration of 2 mM in excess of MgCl2
concentration. Either 3 µl of CFm or one of the IPed proteins were added to this NxT at concentrations
comparable to those of CFm. Along with Add-Back proteins, RNA mix (87 µg/µl tRNA, 1.7 mM 2’dATP,
1.4 mM DTT, 43 mM CP, 0.28 u/µl RNase Inhibitor, 2.2% polyvinyl alcohol, and 3 nM SV40L RNA
substrate) was added to NxT. The rest was done as described previously (13, 128).

3.3

Results and Discussion
An assay was used similar to that described in Figure 3, to identify the CFm protein that requires

to be phosphorylated in order for NxT to have 3’ cleavage activity (Fig 20).

Figure 20. Schematic of the Add-Back experiment with CFIm68-Flag protein. Hypothetically, IPpurified CFIm68-Flag protein could rescues the in vitro 3’ cleavage activity of the dephosphorylated HeLa
NxT.
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The HeLa NxT was first dephosphorylated to render it 3’ cleavage inactive. One of the CFm
proteins, CFIm68, CFIm59, CFIm25, Clp1, or Pcf11, was then added back to see if the 3’ cleavage
activity of the dephosphorylated NxT could be rescued by one or more of these proteins. The CFm
protein to rescue the reaction would be the protein with the posttranslational phosphorylation(s) required
for the 3’ cleavage activity.
The CFm proteins for the Add-Back were obtained by IP from either HeLa cells stably expressing
one of the following Flag-tagged proteins, CFIm68, CFIm59, CFIm25, or Clp1, or in the case of Pcf11,
from CFm via Pcf11 antibody bound to AG beads.
HeLa NxT was treated with CIP for 30 min at 30°C. Immediately after that, CIP was inhibited with
EDTA, 2 mM above the MgCl2 concentration of the NxT (13). Together with all the standard cleavage
components and 3 nM SV40L RNA substrate, either 2, 3, 4, or 5 µl of one of the IP proteins were “added
back” to the now-dephosphorylated NxT, one of those amounts being equivalent or close to being
equivalent to 3 µl of CFm, i.e. the amount needed to rescue cleavage.

Figure 21. 3 µl of CFm rescues 3’ cleavage of
dephosphorylated HeLa NxT. R.C. (5’ fragment/ uncleaved
RNA) in percent is at the bottom of the gel. Input lane is RNA
alone. u=units. M stands for mock treatment, in which CIP buffer
without any CIP was added to the sample. Plus and minus signs
indicate presence and absence of the component specified to the
left of the gel.
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Figure 21 shows that 3 u of CIP can efficiently inhibit 3’ cleavage of 3 µl of NxT. The same figure also
shows that 3 µl of CFm is the minimum amount necessary to rescue cleavage to 27 % efficiency.
Figure 22 shows the IP and Add-Back of CFIm68-Flag protein. Figure 22A is a western blot which
demonstrates that the amounts of CFIm68 in the IP elution (E) and in the CFm are nearly the same,
quantifications of 118 to 100, respectively. For Figure 22A, 50 µg of NxT was loaded as a positive control
sample. Input is 50 µg of lysate made from HeLa cells stably expressing CFIm68-Flag. E denotes elution
of the protein indicated above the brackets. Since CFIm68 bands in elution lanes are Flag-tagged, the
mobility of these bands is slower than those in the control lanes, where CFIm68 is endogenous. Western
blot shows two bands for the CFIm68 protein, the most likely explanation for this is that those are CFIm68
and its isoform, CFIm72.
In Figure 22B, the first seven lanes are all controls. Input RNA is SV40L RNA loaded without
addition of any other in vitro 3’ cleavage components. CFm indicates a standard 3’ cleavage reaction
except that NxT is replaced by CFm. This reaction was done to make sure that CFm does not have any
significant cleavage activity of its own. NxT, lane 3, is a standard 3’ cleavage reaction. NxT (M) is a mock
reaction of CIP treatment. Here CIP buffer instead of CIP enzyme was added to the NxT, followed by
EDTA treatment to quench Mg2+, followed by a salt buffer instead of CFm for Add-Back, and finally
followed by the addition of all the required in vitro 3’ cleavage reaction components. Lane 5 is a negative
control for the Add-Back reaction, where NxT was subjected to the following sequence of treatments: CIP
treatment, EDTA treatment, salt buffer, and finally the rest of the 3’ cleavage reaction components. CFm,
lane 6, is the same as lane 5 except that 3 µl of CFm were added as Add-Back (this is the positive control
for the Add-Back reaction). In lane 7, Flag peptide, which is normally used to elute Flag-tagged proteins
from the beads, was added in the Add-Back step. Lanes 8 to 11 indicate the amount (µl) of CFIm68-Flag
protein added in the Add-Back step.
Lane 3 shows that the 3’ cleavage conditions are efficient. Lane 4 indicates that the CIP buffer is
not interfering with the cleavage reaction. Lane 5 demonstrates that 3’ cleavage can be inhibited with CIP
enzyme, while lane 6 shows that it can then be restored by addition of CFm (3 µl). Lane 7, shows that
Flag peptide, when added as Add-Back, does not rescue 3’ cleavage activity. Lanes 8 to 11 show that
CFIm68-Flag does not rescue 3’ cleavage when it is added at concentration either similar to CFIm68
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concentration of CFm, below, or above that concentration. This is evidence that CFIm68 is not the protein
whose dephosphorylation leads to loss of in vitro 3’ cleavage activity.

Figure 22. IP-derived CFIm68-Flag protein does not rescue 3’ cleavage activity of the
dephosphorylated NxT. A. NxT and CFm serve as controls. Bracket specifies IP samples. Input is HeLa
cell lysate (stably expressing CFIm68-Flag protein) before it was used for the IP. E, elution. Quant is
quantification of the western blot, where CFm is set to 100%. B. R.C. (5’ fragment/ uncleaved RNA) in
percent is at the bottom of the gel. Input lane is RNA alone. u=units. M stands for mock treatment, in
which CIP buffer without any CIP was added to the sample. Add-Back identifies components added to
CIP treated NxT.
Figure 23 shows the IP and Add-Back of CFIm59-Flag protein. This figure has the same controls
as those described in Figure 22. Quantifications of Figure 23A demonstrates that 3.2 µl of CFIm59-Flag
are equivalent to the amount of CFIm59 in 3 µl of CFm. Neither 2, 3, 4, or 5 µl of CFIm59-Flag protein are
capable of rescuing the 3’ cleavage reaction of the dephosphorylated NxT. Figure 23B does not contain a
3.2 µl Add-Back sample, which would be equal to the exact CFIm59 amount in 3 µl of CFm, however, it is
expected that if CFIm59-Flag were able to rescue cleavage, then in such a case, there would be partial or
minimal 3’ cleavage product in either lanes 8 or 9 (3 and 4 µl of CFIm59-Flag). Based on these results, it
appears that CFIm59 cannot rescue 3’ cleavage activity.
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Figure 23. IP-derived CFIm59-Flag protein
does not rescue 3’ cleavage activity of the
dephosphorylated NxT. A. CFm serves as
positive control. Bracket specifies IP samples.
Input is HeLa cell lysate (stably expressing
CFIm59-Flag protein) before it was used for the
IP. E stand for elution. Quant is quantification of
the western blot, where CFm is set to 100%. B.
R.C. (5’ fragment/ uncleaved RNA) in percent is
at the bottom of the gel. Input lane is RNA alone.
u=units. M stands for mock treatment, in which
CIP buffer without any CIP was added to the sample. Add-Back identifies components added to CIP
treated NxT.
Figure 24 shows the IPs and Add-Backs of CFIm25-Flag and Clp1-Flag proteins. This figure has
the same controls as those described in Figure 22. Quantifications of Figure 24A show that 4.8 µl of
CFIm25-Flag is equivalent to the amount of CFIm25 in 3 µl of CFm (top panel). Bottom panel of the same
figure shows that 4.8 µl of Clp1-Flag is equivalent to the amount of Clp1 in 3 µl of CFm. If either CFIm25
or Clp1 is the protein that can rescue 3’ cleavage activity, then Add-Back in lanes 10 or 14 (Fig 24B),
should show at least some 3’ cleavage recovery as compared to 58% cleavage recovery of the positive
control reaction (lane 5). However, there is not any 3’ cleavage rescue by either of the proteins at
quantities from 2 to 5 µl. We conclude that CFIm25 and Clp1 are not able to rescue cleavage of the
dephosphorylated NxT.
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Figure 24. Neither the IP-derived CFIm25-Flag nor Clp1-Flag are capable of rescuing the 3’
cleavage activity of the dephosphorylated NxT. A. CFm serves as control. Bracket specifies IP
samples. Input is HeLa cell lysate (stably expressing CFIm25-Flag or Clp1-Flag protein) before it was
used for the IP. E stand for elution. Quant is quantification of the western blot, where CFm is set to 100%.
B. R.C. (5’ fragment/ uncleaved RNA) in percent is at the bottom of the gel. Input lane is RNA alone.
u=units. M stands for mock treatment, in which CIP buffer without any CIP enzyme was added to the
sample. Add-Back identifies components added to CIP treated NxT.
Figure 25 shows the IP and the Add-Back of Pcf11 protein. This IP is slightly different from all the
previous ones in that the lysate for it was made from untrasfected HeLa cells and instead of Flag Affinity
Beads, a combination of Pcf11 antibody bound to protein AG beads was used to precipitate Pcf11
protein. In addition, because Pcf11 was not successfully eluted from the antibody/AG bead complex via
acid elution (data not shown), Pcf11/AG beads suspension was used for the Add-Back reactions. The
reasoning is that the bead-bound Pcf11 will be in equilibrium with a small amount of free Pcf11, which can
participate in the add-back, or the entire complex might assemble on the beads. Figure 25 has the same
controls as those described in Figure 22. Figures 25A and B show two identical western blots of two
identical IPs for Pcf11 and Clp1. Both Figure 25A and B were done in same manner, however, while
elutions from 20B were used for Add-Back, Figure 25A shows clearly defined bands of Pcf11. Through
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Pcf11 quantifications and averaging of Figure 25A and B, it was calculated that 4.4 µl of Pcf11 IP is
equivalent to the amount of Pcf11 in 3 µl of CFm. Bottom panels of Figure 25A and B show that Clp1 was
added together with Pcf11, during Add-Back reactions in Figure 25C. Figure 25C demonstrates that
though bound in a complex with Clp1, neither 4 nor 5 µl of Pcf11 have the ability to restore 3’ cleavage. It
was concluded that Pcf11 in complex with Clp1 cannot restore 3’ cleavage of the dephosphorylated NxT.

Figure 25. IP-derived Pcf11-Clp1 complex does not rescue 3’ cleavage activity of the
dephosphorylated NxT. A. IP was carried out with Pcf11 antibody bound to AG beads. CFm serves as
control. Bracket specifies IP samples. Quant is quantification of the western blot, where CFm is set to
100%. Pcf11/AG Beads represents samples where half of the sample is IPed Pcf11 protein and the other
half is anti-Pcf11 antibody/AG bead complex. Upper panel and lower panel were western blotted with
Pcf11 antibody and Clp1 antibody, respectively. B. This IP was carried out in the same manner as in
panel A and was used for Add-Back in panel C. C. R.C. (5’ fragment/ uncleaved RNA) in percent is at the
bottom of the gel. Input lane is RNA alone. u=units. M stands for mock treatment, in which CIP buffer
without any CIP was added to the sample. Add-Back identifies components added to CIP treated NxT.
Beads/Antibody represents a sample where the complex of anti-Pcf11 antibody bound to AG beads was
added as Add-Back.
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In Figure 26, we attempted to IP Pcf11 without its binding partners Clp1 and CFIm68 This was
done by either washing AG beads/ Pcf11 antibody-bound protein complex with 0.1 % SDS-containing
buffer (IP2) or by adding SDS to 0.1 % during the incubation step (IP3) (146). Once purified, Pcf11 alone,
without its binding partners, would then be used in Add-Back. IP1 was the control IP done without the use
of SDS. Beads/Antibody is a control sample consisting of just the indicated components. UnbndFrc is
unbound fraction of the HeLa cell lysate collected after the IP. All samples were probed for Pcf11,
CFIm68, and Clp1. Quantification for each protein was normalized to IP1. Quantifications for all three IPs
show that neither washing nor incubating with 0.1% SDS led to dislodging of CFIm68 or Clp1 from Pcf11.
Although IP2 appears to work better than IP3, we were not able to IP Pcf11 without its binding partners.

Figure 26. Neither the 0.1% SDS wash
step nor addition of 0.1% SDS during
the IP prevent CFIm68 and Clp1 from
co-IPing together with Pcf11. IP was
carried out with Pcf11 antibody bound
to AG beads. CFm serve as control.
Beads/Antibody represents a sample
where Pcf11 antibody bound to AG
beads was used as western blot
control. UnbndFrc stands for unbound
fraction of an IP. IP1 is the control IP in
which SDS was not used. IP2 beads
were washed three times with buffer
containing 0.1% SDS. For IP3 0.1%
SDS was included during the IP. Quant is quantification of the western blot, where quantification of IP1
(control IP) was set as a reference point of 1.
3.4

Conclusion
From the Add-Back experiments above, it appears that neither CFIm68, CFIm59, CFIm25, Clp1,

nor Pcf11 can restore the in vitro 3’ cleavage activity of the dephosphorylated NxT. However, Figures 25
and 26 show that Pcf11 IPs in a protein complex with CFIm68 and Clp1, and possibly some other factors.
From other IP experiments not shown here, it was observed that Clp1 co-IPs with Pcf11, CFIm68 with
CFIm25, CFIm25 with CFIm68, CFIm59 with CFIm25, and Clp1 with CFIm68. In addition, it may be that
these IPs contain CPSF as was the case for another group (76). This group found that in the IP and the
binding experiments, Clp1 can be pulled down together with CFIm59, CFIm68, CFIm72, CFIm25, and
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CPSF100 but not CstF64 or PAP. It appears that the IPs used here for Add-Backs, may contain more
than one type of protein, or a combination of two to four or even more proteins. Therefore instead of
adding back one protein per reaction, it appears that each Add-Back experiment was supplemented with
a complex consisting of a mixture of CFIm and CFIIm proteins; where most likely each complex differed
from the other protein complexes in its protein composition and concentration. The results of this section
did not support the hypothesis that one of the better known proteins of the CFm fraction can rescue 3’
cleavage activity of a dephosphorylated NxT.
Previous research shows that a highly purified CFIIm fraction contains >15 proteins, it may be
that one of these proteins, with exclusion to the ones we tested, contains the phosphate modification
required for the 3’ cleavage reaction (76).
It may be possible that more than one protein requires to be phosphorylated to rescue the 3’
cleavage during Add-Back. It may also be that the Add-Back experiments did not work, because the
protein stoichiometry within each IPed protein complex was not favorable for the 3’ cleavage reaction. In
other words protein complex was lacking in the amount of one or more proteins from CFIm and/or CFIIm
fractions. So it could be useful to do Add-Back reactions with various combinations of each IP. Once a
particular combination of these IPs is found to rescue cleavage, then the IPs within that combination can
be dephosphorylated one at a time to determine which of them contributes to loss of the 3’ cleavage
activity after the CIP treatment of the NxT. The IPed protein complexes can then be analyzed by western
blotting to look for any differences in protein content and concentration between complexes which are and
are not affected by dephosphorylation. This could help to identify protein(s) responsible for loss of 3’
cleavage as a result of CIP treatment. Another possibility that we cannot rule out is that the Flag peptide
used to elute the proteins from the beads (except for Pcf11) interferes with the cleavage reaction, though
since the sequence is so unrelated to any of the cleavage factors this seems unlikely.
It is also possible that the Flag-tag purified protein complexes could not reintegrate with the
already assembled 3’ processing proteins of the dephosphorylated NxT. If CFm fraction is assumed to
rescue 3’ cleavage activity by reintegrating with the rest of the protein complex, while the Flag-IPs contain
a number of CFm proteins, then it seems that the Flag-IP proteins would be able to reintegrating with the
rest of the complex. However, the number of different proteins per Flag-IP is smaller, which could make it
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more difficult for this smaller complex of proteins to reintegrate with other CFm proteins, some of which
are known to be strongly bound to each other.
Another possibility for why the Add-Back reactions failed to restore 3’ cleavage, is that the
proteins became dephosphorylated before or during the Flag-IP procedure. While for the preparation of
the HeLa NxT from the suspension cells (147), the cells are lysed in such a way that cytoplasm is
separated from the nuclei before nuclei are lysed. In this way, NxT is not exposed to cytoplasmic proteins,
though some leakage surely occurs. The NxT is then used to prepare CFm, which is capable of rescuing
the 3’ cleavage activity of the dephosphorylated NxT. However, the Flag-IPs were carried out using the
whole cell lysates, where it is assumed that both cytoplasm and nuclei are lysed together. In the whole
lysate the 3’ processing proteins could have been dephosphorylated by cytoplasmic phosphatases even
before they were subjected to Flag-IPs. One way to control for possible interference from cytoplasmic
phosphatases is by re-phosphorylating the Flag-IPed proteins with MgCl2 and ATP in HeLa NxT (87). The
Flag Bead bound proteins would then be precipitated and washed with buffer to remove the NxT. Such
steps would be done to make sure that the IPed proteins are phosphorylated before they are used in AddBack reactions.
Lastly, I took care to add-back an amount of protein close to the amount found in our positive
control, the DEAE-CFm fraction. Thus we can be sure that the added back amount was sufficient
according to the CFm postitive control. However, it is possible that in HeLa cells only a tiny fraction of the
unidentified phosphorylated cleavage factor occurs in phosphorylated form, and this form is localized to
the sites of processing. When the entire population of protein is IP’d, the majority of recovered protein is
in the unphosphorylated, inactive form. An experiment where the lysate is subjected to kinase-favorable
conditions (5 mM MgCl2 + 2 mM ATP) before IP, may enrich the phosphorylated form of the proteins. IP
of that hyper-kinased extract might yield a higher fraction of phosphorylated factors. Gamma-ATP could
be included to visualize any labeled proteins in the precipitate.
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CHAPTER FOUR: Additional Studies of ATP as a Cofactor that Binds to Clp1 Protein
4.1

Introduction
The experiments below were tried in addition to those described in Chapter 2 where Clp1 was

examined as the possible target of ATP binding; the interaction that could potentially result in 3’ cleavage
of Ad2L3 RNA. The 3T3 mouse embryonic fibroblast (MEF) wt and mutClp1 cells were obtained from
Javier Martinez group from the Institute of Molecular Biotechnology, Vienna Austria. The mutClp1 MEF
cell line contained the K127A substitution, a mutation in the conserved P-loop/ Walker A motif. K127 is
known to binds ATP at its phosphate tail. The mutation of K127 to alanine impairs the 5’ phosphorylation
of RNA (148). The plan was to test NxTs made from wt and mutClp1 MEF cell for their 3’ cleavage
activities with Ad2L3 RNA and ATP. It was hypothesized that if the 3’ cleavage activity of mutClp1 MEF
NxT with Ad2L3 RNA and ATP is absent or inhibited in comparison to that of wtClp1 MEF NxT with Ad2L3
RNA and ATP, then this would point to possible ATP to Clp1 binding as the requirement for the 3’
cleavage activity.
The wt and mutClp1 NxTs were made from 3T3 MEF cells. These NxTs were first tested for 3’
cleavage activity with SV40L RNA, a substrate that does not require ATP for its 3’ cleavage activity. In the
case of SV40L, both wt and mutClp1 NxTs were expected to have 3’ cleavage activity. The same NxTs
would then be used on the ATP-requiring Ad2L3 substrate. With Ad2L3 substrate and ATP, it was expect
that wtClp1 NxT, where Clp1 to ATP binding is intact, would generate 3’ cleavage activity. However, if
ATP is acting on 3’ cleavage activity through the Clp1 protein then mutClp1 NxT, for which ATP to Clp1
binding is impaired, would yield inhibited or no 3’ cleavage activity with the Ad2L3 RNA substrate.
4.2

Experimental Procedures

4.2.1

General Ryan Lab MEF Nuclear Extract Preparation Protocol
Each 15 cm tissue culture plate was washed three times with 10 ml of 1XPBS. About 5 ml of

1XPBS were added to each plate, cells were scraped with rubber policeman, and centrifuged at 2,000
rpm for 5 min. The cells were then resuspended in 3 ml of Buffer A (10 mM K-Hepes pH 7.9, 1.5 mM
MgCl2, 10mM KCl, and 0.5 mM DTT). Once in Buffer A, cells were allowed to swell on ice for 10 min. The
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cells were then transferred to 7 ml dounce homogenizer, dounced 20 times using B type pestle to break
the cell membrane and to release the nuclei. Nuclei were then centrifuged at 4,000 rpm for 10 min. Pellet
nuclei volume (PNV) was estimated, resuspended in 1.5XPNV of Buffer C (20 mM Na-Hepes pH7.9, 0.42
M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT, and 25% glycerol), incubated on ice
for 30 min with intermittent pipetting to break the nuclei, and centrifuged at 13,200 rpm for 15 min at 4⁰C.
The supernatant was dialyzed in 100 ml of Buffer D 40 (20 mM Tris-Cl pH 7.9, 0.2 mM EDTA, 0.5 mM
DTT, 0.5 mM PMSF, 40 mM (NH4)2SO4, 10% glycerol) for 2 hours.
4.2.2

General Martinez Lab MEF Nuclear Extract Preparation Protocol
Cells were trypsinized and centrifuged for 2 min at 1,200 rpm. Cell pellet was washed with 5 ml of

1XPBS, spun, washed with 1 ml of 1XPBS, and spun again. The cell pellet was then resuspended in one
volume of Buffer A (10 mM K-Hepes pH 8.0, 1 mM MgCl2, 10 mM KCl, 1 mM DTT) and incubated for 15
min on ice. The 1 ml syringe fitted with 23 gauge needle was washed with Buffer A to displace air, the
swollen cells in Buffer A were then lysed by drawing them into the syringe and rapidly ejecting against the
tube wall. This step was repeated for a total of five times. The lysed cells were centrifuged for 1 min at
13,000 rpm. The resulting pellet was resuspended in two-thirds of PCV in Buffer C (20 mM K-Hepes
pH8.0, 1.5 mM MgCl2, 25% glycerol, 420 mM NaCl, 0.2 mM EDTA, 0.1 mM PMSF, and 1 mM DTT),
incubated on ice with stirring for 30 min, and centrifuged for 5 min at 12,000 rpm. The supernatant was
dialyzed for 1 hour in Buffer D 40.
4.3

Results and Discussion

4.3.1

General Ryan Lab MEF Nuclear Extract Preparation Protocol
With some alterations, the protocol for making NxTs in this section is similar to that of Dignam et

al., (147). HeLa or MEF cells were at first swollen by incubating their cell pellets in 4-10 ml of a low salt
buffer (Buffer A). The swelling of the cells made it easier to break the cytoplasmic membrane and release
the intact nuclei via douncing. Next, NxTs were made from the pelleted nuclei. Nuclear proteins were
released from the nuclei by incubating them in 1.5 PNV of Buffer C (high salt buffer) with agitation on ice
for 30 min. The resulting NxTs were dialyzed for 2 hours.
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Either seven or nine (15 cm) plates (300 µl-500 µl packed cell volume (PCV)) of wt or mutClp1
MEF cells were used to make one NxT at a time (Fig 27). Figure 27 shows some of NxTs made from
HeLa and MEF cell using Ryan Lab NxT protocol, while several other attempts to make these extracts,
using the same protocol, are not shown here.

Figure 27. Using Ryan Lab Protocol to make multiple NxTs from
HeLa cell as well as from wt and mutClp1 MEF cells. NxTs were
made according to Ryan Lab Protocol, except for HeLa NxT (S.
Cells) which is a positive control reaction and stands for NxT made
from suspension HeLa cells. Lanes 3 and 7 are 3’ cleavage
reactions with wt or mutClp1 concentrated cytoplasmic fractions.
Lanes 4, 5, and 8 are 3’ cleavage with different wClp1 MEF NxTs.
Lanes 6 is 3’ cleavage reactions with mutClp MEF NxT. 5’ and 3’
indicate the upstream and downstream products, respectively.

Using Ryan Lab NxT Protocol, NxT made from HeLa cells had good 3’ cleavage activity (not
shown here), while none of the NxTs made from MEF cells resulted in 3’ cleavage active NxTs (Fig 27,
lanes 3-8). The concentrated cytoplasmic fractions used in Figure 27 were not expected to give any 3’
cleavage activity but were used here for comparison as the negative control reactions. Unlike HeLa NxT
(lane 2), all of the 3’ cleavage inactive reactions done with the MEF NxTs contained high levels of RNA
degradation. One explanation as to why MEF NxT contained no 3’ cleavage activity could be that the
MEF cells contain high RNase activity that is not present in HeLa cells. HeLa cells are the established
standard cells for use in in vitro 3’ cleavage reactions and they are known for their low levels of RNase
activity. However, the 3’ cleavage active wt and mutClp1 MEF NxTs had to be obtained to proceed with
Clp1/ATP/ Ad2L3 RNA experiments. The goal was to determine if altering NxT preparation protocol would
result in the 3’ cleavage active wt and mutClp1 MEF NxT. It was decided to try a somewhat different
protocol from another lab, the General Martinez Lab NxT Protocol, because they published one
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successful in vitro cleavage experiment (148), but also told us they experienced difficulties similar to our
own.
4.3.2

General Martinez Lab MEF Nuclear Extract Preparation Protocol
In this protocol the cell pellet was resuspended and incubated in 1 PCV of Buffer A (low salt

buffer) for 15 min. The cells were then passed 5 times through a 1 ml syringe fitted with 23 gauge needle,
followed by centrifugation to precipitate the nuclei. The nuclei were then resuspended in 2/3 PCV of
Buffer C (high salt buffer) and incubated with agitation on ice for 30 min. The NxT was dialyzed for 1 hour.
The main differences between the Ryan and Martinez protocols were the way the cytoplasmic
membrane was lysed, dounce vs needle, and also in that for the Martinez protocol, the lysing of the nuclei
was done in a smaller volume of Buffer C, hence the more concentrated NxTs. Multiple wt and mutClp1
MEF cell NxTs were made using to Martinez Lab Protocol. Under the conditions of this protocol, three out
of five separately made HeLa NxTs had 3’ cleavage activity (Fig 28, lanes 13, 14, and 17).

Figure 28. Using Martinez Lab Protocol to
make multiple NxTs from HeLa cell as well
as from wt and mutClp1 MEF cells. NxTs
were made according to Martinez Lab
Protocol, except for HeLa NxT (S. Cells) which
is a positive control reaction and stands for
NxT made from suspension HeLa cells. Lanes
3-7 are 3’ cleavage reactions with wtClp1 MEF
NxTs made on different days. Lanes 8-12 are
3’ cleavage reactions with different mutClp1
MEF NxTs. Lanes 13-17 are 3’ cleavage
reactions with different HeLa NxTs made with
Martinez Lab Protocol. 5’ and 3’ indicate the
upstream and downstream fragments,
respectively. R.C. (5’ fragment/ uncleaved
RNA).

There was a wide variability in the amount of the 3’ cleavage activity between these HeLa NxTs.
Therefore it appears that the Martinez protocol may not be good for reproducibility. The same protocol
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when used with wt or mutClp1 MEF cells resulted in one in ten 3’ cleavage active NxTs (Fig 28, lane 8).
Figure 28 shows that when the Martinez protocol is used, RNA degradation with MEF cells is present but
is not as extensive as that with Ryan protocol (Fig 27). Although Martinez protocol yielded some 3’
cleavage activity with MEF cells, this method did not generate reproducible result.
The results from Figures 27 and 28 suggest that the protocols used were not effective at making
NxTs from MEF cells, and had to be altered to find the optimal method for making reproducibly active
NxTs. Several alterations to the Martinez protocol were tried. One of the alterations to the protocol was
adding general phosphatase inhibitors (50 mM NaF and 10 mM β-phosphoglycerol) during the nuclei
lysing step. This was done to constrain any phosphatases that could be inhibitory to the 3’ cleavage
activity. Another amendment to the Martinez protocol was treating of the MEF NxTs with DNaseI just
before the 3’ cleavage reaction. The reasoning for DNaseI treatment was that since the 3’ processing
occurs co-transcriptionally, then fragmenting of the DNA could release more of the 3’ processing proteins
into the lysate and hence improve 3’ cleavage activity of MEF NxTs. Neither the phosphatase inhibitors
nor the DNaseI treatment were able to improve the 3’ cleavage activity of the MEF NxTs (not shown).
Another modification of the Martinez protocol was to halve the salt concentration of already low salt Buffer
A, in attempt to improve the swelling of the cells in this buffer. Lowering the salt concentration of the swell
buffer did give an improved 3’ cleavage activity, however, this activity was hard to reproduce.
4.4

Conclusion
Most 3’ cleavage reactions with MEF NxTs contain some RNA degradation. This RNA

degradation was not due to RNase contamination of any of the buffers or the labware used to make these
NxT. There was no RNase contamination during the experiments because the same buffers and labware
were used to make HeLa NxTs, which did not contain similar RNA degradation during in vitro 3’ cleavage
reactions.
It was conclude that the MEF cells have some endogenous 3’ pre-mRNA in vitro cleavage activity
but the conditions that give reproducibly active MEF cell NxTs were not established. HeLa cell NxTs are
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known to give very good 3’ cleavage activity, however, aside from their low RNase activity, other reasons
for their efficiency are not understood.
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